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ABSTRACT 
Background 
Basic patient factors such as age, sex, and comorbidities are poorly understood in 
the context of re-operation rates and patient-reported outcome measures after 
total hip replacement (THR) surgery. 
Aims 
The aims of this thesis were to investigate: 
1. If comorbidity measures developed for mortality outcomes also are 
applicable for re-operations. 
2. How age influences health-related quality of life (HRQoL). 
3. If sex/age interacts with self-administered Charnley classification in 
regards to HRQoL. 
4. The generalizability of HRQOL estimates. 
5. If antidepressant use impacts patient-reported outcomes. 
Methods 
All studies were based upon the Swedish Hip Arthroplasty Register (SHAR) 
database. For study I, data from SHAR was cross-matched with the National 
Patient Register through which 3 different comorbidity measures were 
calculated: the Charlson score, the Elixhauser score, and the Royal College of 
Surgeons (RCS) Charlson’s score. The three scores were then compared using 
survival analysis with implant re-operation performed between 0 to 2 years and 2 
to 12 years. 
In study II and III we used the SHAR’s PROM database with HRQoL outcomes 
as measured by EQ-5D and EQ-VAS. In study II we modeled age using linear 
regression in combination with restricted cubic splines in order to study the 
relationship between age and HRQoL. In study III we used linear regression with 
interaction terms evaluated by ANOVA-tests, subset, and EQ-5D dimension 
specific analyses. 
In study IV we linked the SHAR’s PROM database to the National Patient 
Register and a Danish cross-sectional sample. The Charlson comorbidity 
measure was calculated as in study I, and effect modification by country was 
investigated through terms of interaction, evaluated as in study III. 
In study V, we cross-matched the SHAR’s PROM database with the Prescribed 
Drug Register. We calculated the usage of antidepressants using regular 
expressions. Measures for compliance, treatment change, and indication were 
retrieved from the prescription text. 
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Results 
Study I 
0-2 years, only the Elixhauser score showed significant risk increase with 
increased score for both 1-2 and ≥ 3 comorbidities. The predictive C-statistic in 
this period for the Elixhauser score was poor, 0.52. None of the measures proved 
to be of any value between 2-12 years. 
Study II 
Both the EQ-5D index and EQ VAS exhibited a non-linear relationship with age, 
they were fairly unaffected by age until the patient’s late sixties, after which it 
had a negative impact. 
Study III 
We found that women in category C had a poorer EQ-5D outcome compared to 
men. This effect was mostly due to the fact that women failed to improve in the 
mobility dimension, only 40% improved, while 50% of men improved. Age did 
not interact with Charnley class. We also found that the classification performed 
best without splitting or aggregating classes.  
Study IV 
Danish patients had an overall higher EQ-5D index and EQ VAS than Swedish 
patients (p-value < 0.001). After regression analysis, the estimated coefficients 
for sex, age, or the Charlson score did not differ between countries for either the 
EQ-5D index (p-value = 0.83) or EQ VAS (p-value = 0.41) one year after THR. 
Study V 
Antidepressants were used by 9% of the cases (n = 954).  Patients using 
antidepressants had poorer HRQoL, more pain, and experienced less satisfaction. 
Preoperative antidepressant use was independent of patient-reported 
anxiety/depression in predicting PROs one year after THR. Discontinuation of 
treatment was negatively associated with pain and satisfaction at one year. 
Conclusions 
Study I 
We failed to validate any of the scores for re-operations after total hip 
arthroplasties, although the Elixhauser score may be useful for estimating the 
comorbidities relevant to the risk of re-operation within 2 years. The comorbidity 
associated risk increase was small, and is undoubtedly best suited to the study of 
large samples and not individual patients. 
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Study II 
There is a non-linear relationship for age and HRQoL in patients receiving THR; 
resulting in residual confounding if treated as a simple linear term or 
categorically in the regression. The implication of this is important, as age is a 
common confounder. The same applies to the preoperative EQ-5D index and EQ 
VAS.  
Study III 
The self-administered Charnley classification is a reliable instrument with 
interesting properties easy to utilize in everyday clinical practice. There is also 
strong evidence that women in Charnley class C fail to improve their mobility as 
much as men. 
Study IV 
There are clear similarities in how basic predictors influence patient-reported 
outcomes in patients with THR in Sweden and Denmark. Apparent cultural, 
social, and other such differences among these countries are not reflected in 
these predictors.  
Study V 
Antidepressants have a negative influence on patient-reported outcomes 1 year 
after THR, independent of the pre-operative EQ-5D anxiety/depression 
dimension. We also found that discontinuation of treatment prior to surgery is 
associated with poorer outcomes in the dimensions of pain and satisfaction. 
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1 INTRODUCTION 
Prior to total hip replacement (THR) surgery, patients with hip osteoarthritis 
were offered treatments such as resection arthroplasty, weight distribution, 
arthrodesis and even bed rest with hip traction [1], [2]. When THR emerged as a 
viable treatment alternative it revolutionized orthopaedics, referred to by some as 
“the operation of the century” [3]. The first successes of THRs appeared in the 
late 1930s and 30 years later, with Charnley’s ground-breaking work on low-
friction arthroplasties [4], it truly caught on. The indications have since then 
widened; today even 100 year old patients are being operated [5].  
1.1 OUTCOMES 
The success of a THR is measured by 4 main outcome categories: (1) patient 
survival, (2) implant survival, (3) other adverse events, and (4) patient-reported 
outcome measures (PROM). Although technical outcomes such as component 
positioning, soft tissue preservation or leg length restoration can be viewed as a 
type of outcome, they all aim at addressing issues within the 4 main outcomes.  
1.1.1 Patient survival 
The patient surviving the surgery is the most fundamental premise for any kind 
of surgery. The mortality associated with the THR procedures occurs soon after 
the surgery; effects related to bleeding, pulmonary embolism, and other per-
operative causes quickly decline during the first months [6].  The 90-day 
mortality rate is the most common mortality measure [7], although some studies 
report in-hospital mortality [8] or 30-day mortality [9].  
Prior to the aseptic technique introduced in late 19th century, mortality rates of 
50% were common [10]. Even today there seems to be improvement in the 
mortality rates [11]–[13], and the current 90-day mortality in Sweden is less than 
1% [14], similar to rates in other countries [6], [8], [11], [12], [15]–[19].  
1.1.2 Implant Survival 
Implant survival relates to the survival of the implanted material. There are two 
terms frequently used for estimating implant survival, re-operations and 
revisions: 
 Re-operation is a wider definition whereby any further surgery affecting 
the operated hip is included. 
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 Revision is a subgroup of re-operations including only the surgeries 
where the implant is exchanged.  
The Swedish Hip Arthroplasty Register (SHAR) has from its start in 1979 used 
re-operations as a measurement [20]. Re-operations and revisions can be further 
subdivided into the underlying cause: 
 Infection: Often referred to as periprosthetic joint infection, it occurs 
most frequently within the first year of surgery [21], [22] with an 
estimated 2 year cumulative incidence of 1% [23].  
 Fracture: Periprostethic fractures occur both early and late after THR. 
Early re-operations within 6 months are frequently technical 
complications and are associated with cementless stems [24]. The 
average time to fracture is 7 years, and the estimated cumulative 
incidence about 1% for 5 years, and 3-4% at 10 years [25], [26]. 
 Instability: A THR dislocates more easily than the innate hip joint. The 
incidence of dislocation is difficult to measure and ranges in international 
studies between 1 and 5% [27]–[30]. Between 2009 and 2012, 0.3% in 
Sweden were re-operated within 2 years due to dislocation [31, p. 52]. 
Most dislocations occur early on, 50%-70% occur within the first 3 
postoperative months [32], [33], although late dislocations (> 5 years) 
more often require re-operation [34].  
 Loosening/lysis: Loosening occurrs when the bone retracts from the 
implant with a radiolucent line visible on x-rays. If the process is 
localized and the implant is clearly not loose, it is referred to as osteolysis 
[35]. Common inflammatory pathophysiology for the processes has been 
hypothesized [36], [37]. The cumulative incidence for 
loosening/osteolysis is 0.2% at 2 years,  0.8% at 5 years, and 2% at 
10 years (study I). 
 Other: There are multiple other causes such as technical failure or 
implant fracture for re-operations that amount to a cumulative 10 year 
incidence of less that 3% (study I). 
The 10 year re-operation rate is currently at an all-time low, less than 5% for 
patients operated due to primary osteoarthritis [14]. This coincides with the new 
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having increasing difficulty in improving on the existing designs [38], currently 
3 stems constitute 99% of all implanted cemented stems in Sweden [31, p. 13].  
1.1.3 Adverse events 
Death and re-operations are only a subset of adverse events after THR. Other 
events such as cardiovascular, thromboembolic events can be equally important, 
while minor events such as urinary tract infection may be quality of care 
indicators. Adverse events in medical practice are fairly common, expected 
around  3-15% [39]–[43], and perhaps even more common in orthopaedics [44]–
[46]. There is currently no validated registry-based tool for the Swedish 
population, although readmissions combined with ICD-codes are reported on a 
yearly basis in Sweden [14]. 
1.1.4 Patient-reported outcome 
The THR indication is primarily to improve quality of life, and is very successful 
at this [3]. Charnley reported in his landmark paper on long-term results in 1972 
that the majority of patients had excellent results regarding pain and walking 
ability [47]. As the indications have widened and patient demographics changed, 
the importance of patient-reported outcome measures (PROMs) have reentered 
center stage [48].  
Furthermore, with the improvement in implant survival and low re-operation, 
PROMs are becoming increasingly important for evaluating THR [49]. Although 
hip resurfacing has fallen out of favor, many of its main proponents argued for it 
because of better PROMs [50]–[52].  
In orthopaedics there are two main types of PROMs: generic measures and 
disease specific measures. Generic measures usually span different health 
domains, and can be used irrespective of the particular disease being studied; this 
has the advantage of allowing comparison between different diseases [53]. 
Generic measures are frequently also referred to as health related quality of life 
(HRQoL). There are 2 main HRQoL instruments used in orthopaedics: 
 Euroqol 5 dimensions (EQ-5D): The EQ-5D™ was developed in the 
late 80s by the EuroQol group as a standardised, non-disease-specific 
instrument for describing and evaluating health states [54]. The tool 
consists of 5 different dimensions and a visual analogue scale (VAS). 
The dimensions are weighted according to a value set in an index where 
values of 0 correspond to states equal to death and 1 to perfect health. 
The 5 dimensions are: 
1. Mobility 
2. Self care 
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3. Usual activities 
4. Pain  
5. Depression 
 Short Form 36 (SF-36): The SF-36® has its roots in the 70s but was 
formalized in the late 80s [55], and is now managed by the Medical 
Outcomes Trust. The tool consists of 36 items that are aggregated into 8 
different domains that in turn can be divided into physical and mental 
health summaries. The domains and summaries are usually expressed on 
a scale ranging from 0 to 100 where higher scores indicate better health 
for that domain. Simpler alternatives to the 36 questions have been 
developed by QualityMetric, SF-12® [56] and SF-8™ [57]. The 8 
domains
1
 are: 
1. Bodily pain 
2. Physical functioning 
3. Role limitations due to physical health 
4. General health 
5. Mental health 
6. Vitality 
7. Social functioning  
8. Role limitations due to emotional health. 
Disease specific quality of life measures and hip specific outcome measures are 
separated by some into two entities [58]. As they are both limited in their extent, 
they are grouped together under disease specific measures in this thesis. There 
are currently 3 commonly used disease specific measures for hip osteoarthritis 
and THR: 
 Harris hip score: The score was originally introduced for evaluating 
acetabular fractures [59, p. 69], but has since been widened to other hip 
related diseases [60], [61]. Harris hip score was originally not intended 
for self-reporting, but studies have shown that this is feasible [62]. The 
score consists of 10 items that are merged into a score ranging from 0 to 
100 where higher scores indicate better hip function.  
 Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC): The WOMAC® score was developed in the 80s and 
consists of 24 items that are summarised into 3 subscales [63]–[65]. The 
subscores range from 0 to 100 where higher scores indicate poorer hip 
function. The 3 subscales are: 
1. Pain 
2. Stiffness  
                                                 
1
 1-4 are part of the physical health summary, 5-8 are part of the mental health summary 
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3. Physical function 
 Oxford hip score: The score consists of 12 items add up to a score from 
12 to 60 where higher scores indicate poorer hip function [66]. The 
scoring was updated by the original authors in 2007; the new score 
ranges from 0 to 48 and has flipped the scale, i.e. higher number 
indicates better hip function [67].  
This is just a handful of the available disease specific hip scores [58], [68] and 
there is an ongoing effort in validating and translating new measures [69], [70]. 
PROMs are generally believed to be less susceptible to interviewer’s bias as the 
majority of them are self-reported, since patients answer the questionnaire 
without any aid from study personnel. The lack of supervision can increase the 
risk of misunderstood questions and skipped answers [71, p. 500]. Recall bias 
can still occur and it is therefore important that the health states are prospectively 
recorded [72]. There is also a risk of response bias, i.e. that the patient responds 
to the survey differently from those non-responding. This stresses the importance 
of maximizing response rates [73]–[75]. 
PROMs are also believed to be more susceptible than other outcomes to cultural 
influence. Dieppe et al. reported large variations between and within countries in 
disease severity when deciding to operate [76]. How these variations affect the 
PROMs is sparsely explored.  
1.2 PATIENT FACTORS 
This thesis is limited to the results regarding patients operated with THR due to 
primary osteoarthritis. In 2012 almost 16,000 patients were operated with a 
primary THR and primary osteoarthritis amounted to more than 80% of all 
surgeries [14]. Other important indications are fractures, idiopathic femoral head 
necrosis, childhood disease and rheumatoid arthritis. Fractures have become 
increasingly common [77], [78] while rheumatoid arthritis has rapidly decreased 
due to efficient disease-modifying anti-rheumatic agents [79]. 
1.2.1 Age 
Age is an important confounder in studying most health related outcomes [80, p. 
5], and perhaps the most commonly adjusted variable. Increased re-operation 
rates for younger patients due to aseptic loosening is today widely recognized 
[31, p. 79], [81]–[86]. On the other hand, the risk of fractures and dislocations is 
higher among elderly. Cook et al. showed that patients age 80 and above have an 
odds ratio of 4.4 (95% confidence interval (CI), 2.9–6.4) for fractures compared 
to patients below 80 [26]. Malkani et al. reported that patients 85 and above were 
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associated with an almost 50% higher relative risk of early dislocation compared 
to patients between 65 and 69 [87].  
As expected, age is also related to mortality within 90 days. SooHoo et al. 
reported an odds ratio of 2.6 (95% CI, 2.2 to 3.0) for patients over the age of 75 
compared to patients between 65 and 75 [88]. Hunt et al. studied over 400,000 
patients and similarly reported an increase in the elderly, although they noted 
that this increase was primarily among men. The Kaplan-Meier 90-day mortality 
estimates for patients age 80 and above were 1.9% for men (95% CI, 1,7 to 2·11) 
vs 1.1% for women (95% CI, 1,0 to 1.2); the corresponding rates for patients 
between 65 and 69 were 0.3% for men (95% CI, 03 to 0.4) vs 0.2% for women 
(95% CI, 0.1 to 0.2) [12]. 
Regarding the impact of age on HRQoL after THR, there is currently no 
consensus [89]. Some studies report decreasing improvement in HRQoL after 
THR with age [90]–[94], while others indicate little effect if any [95]–[99]. 
Furthermore, it has not been properly investigated if the effect of age is similar 
throughout the range of ages, or if there is an accelerated decline for the elderly.  
1.2.2 Sex 
Men compared to women have a marginally higher risk for revisions [81], [86], 
[100], [101, pp. 40, 49] where the risk increases with age [31, p. 79]. The 
Norwegian Arthroplasty Register noted a hazard ratio of 1.3 (95% CI, 1.1 to 1.5) 
[102], while the Australian Orthopaedic Association National Joint Replacement 
Registry reported in 2013 an even smaller difference, hazard ratio 1.06 (95% CI, 
1.02 to 1.1) [85], and Inacio et al. reported on an American cohort of 34,140 
women having an increased risk for revision, hazard ratio 1.3 (95% CI, 1.1 to 
1.5) [103]. Part of these differences could be explained by sex interactions with 
implant type [104]. 
Part of the increased risk may be due to infections [105]. Men are associated 
with increased hazard ratios in Nordic countries ranging between 1.5 and 2.5 for 
periprosthetic joint infection [22], [106], [107], although two large American 
studies fail to confirm these findings [103], [108]. Conversely, some report a 
higher risk for aseptic loosening for women with hazard ratios of 1.3 to 1.4 
[103], [109], although this has not been unanimously shown [82]. Women also 
seem to dislocate 2 times more often than men [27], [29] though Conroy et al. 
could not find any support for this in an Australian cohort of 65,992 patients 
[110]. 
Men have marginally elevated mortality rates [12], [17]. SooHoo et al. reported a 
hazard ratio of 1.2 (95% CI, 1.1 to 1.4) for mortality within 90 days [88]. 
Memtsoudis et al. reported an odds ratio of 1.7 (95% CI, 1.6 to 1.9) for in-
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hospital mortality [8]. McMinn et al. studied the long term mortality and found 
similarly higher mortality rates for men, hazard ratio 1.5 (95% CI, 1.5 to 1.6) 
[111]. 
Sex differences have also been noted for PROMs, although the differences are 
inconclusive. Slover et al. found for 1,357 THR patients that men reported a 4 
points higher improvement for Harris hip score [112], less than 10% of the 
average improvement after a THR (45-50 points) [113], [114]. Smith et al. 
similarly found when studying 1,318 THR patients that men perform better, 
although they only investigated whether a patient reached the maximum Harris 
hip score of 100 [115].  
Hajet et al. could not find any sex differences for the Oxford hip score of 5,038 
patients but the study was compromised by the fact that more than half of the 
patients failed to respond to the survey [116]. Quintana et al. also failed to find 
any significant differences in 590 patients 6 months after THR for the WOMAC 
score [98]: 
 14 points for men vs 16 points for women1  
regarding pain 
 20 points for men vs 23 points for women1  
regarding stiffness 
 22 points for men vs 25points for women1 
regarding physical function 
Somewhat surprisingly they found significant differences favoring men when 
using the SF-36 tool:  
 51 points for men vs 40 points for women2 
regarding physical functioning 
 32 points for men vs 16 points for women2 
regarding role limitations due to physical health 
 56 points for men vs 47 points for women2 
regarding bodily pain 
 34 points for men vs 30 points for women2 
regarding general health 
 40 points for men vs 36 points for women2 
regarding mental component summary scale
1
. 
                                                 
1
 The value is the improvement according to linear regression for healthy patients below 70 years 
of age without the mental component summary scale estimate, i.e. intercept + βsex 
2
 The value is the improvement according to linear regression for healthy patients below 70 years 
of age without the mental component summary scale estimate, i.e. intercept + βsex 
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Judge et al. also looked at the SF-36 physical functioning dimension of 282 
patients and found that women have a lower probability of achieving clinically 
meaningful improvements, odds ratio 0.4 (95% CI, 0.2 to 0.7) [117]. McGuigan 
et al. noted that men have slightly better outcomes for the SF-36 dimensions: 
bodily pain, role limitations due to physical health, mental health, vitality, and 
social functioning [90]. Two more recent studies with mixed hip and knee 
arthroplasty cohorts support these findings [96], [118]. 
Contrasting with this is the large study by Stevens et al. on 653 patients that also 
included BMI. They found that men reported poorer WOMAC outcomes, while 
no relation was seen for SF-36 [119]. Lavernia et al. investigated sex differences 
for 532 patients at a minimum of 2 years after their THR using 5 different scores; 
the WOMAC subscales were the only outcomes that correlated to a higher 
improvement among women but unfortunately they did not attempt to analyze 
their data further using any of the regression methods [120]. 
It is possible that the differences arise due to different control for confounding, 
although if sex had a stronger effect on patient-reported outcomes after THRs, 
the results would most likely have been more consistent.  
1.2.3 Comorbidities 
Comorbidities’ influence on outcome after arthroplasties has lately gained a lot 
of interest. The number of articles in PubMed mentioning both arthroplasty and 
comorbidity has more than quadrupled between 2001 and 2011 (Figure 1). A 
comorbidity can be defined as [121]: 
“…diseases or medical conditions unrelated in etiology or causality to 
the principal diagnosis that coexist with the disease of interest”. 
In the THR context this interprets as any disease other than the one behind the 
reason for the THR.  
 
                                                                                                                                 
1
 A summary of the four different mental health components (vitality, social function, role 
emotional, and mental health) 
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1.2.3.1 Indices and scores 
Due to the multitude of different comorbidities they are frequently summarized 
in scores/indices. The ASA score is probably the most commonly known 
comorbidity measure [122]. While the ASA score impacts THR outcomes  
[123], [123]–[125], it is generally not available in administrative databases. 
Administrative databases that log institutional and non-institutional care usually 
contain ICD codes indicating both the main disease and comorbidities of 
importance. The availability of the codes has spurred the development of ICD-
based scores as illustrated by Figure 1. Unfortunately there are different versions 
of ICD-codes requiring translation and validation between different versions. For 
instance, the US uses ICD-9 while we in Sweden use version 10 since 1997, and 
only 15% of studies comparing and evaluating comorbidities use both systems 
[126]. 
There are currently two commonly used ICD-based scores that are available for 
both ICD -9 and ICD-10: the Charlson comorbidity score or index [127] and the 
Elixhauser comorbidity measure [128]. The Charlson score has also been 
simplified and adapted to a surgical setting by the Royal College of Surgeons 
(RCS) [129].  
Figure 1. Number of articles according to Pubmed that mention 
comorbidities. 
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According to the Charlson score comorbidities have been found to increase 
overall revision rates. Johnsen et al. reported for scores above 2, hazard ratios of 
2.3 (95% CI, 1.6 to 3.5) for the first month, 3.0 (95% CI, 2.1 to 4.5) between one 
month and six months, and 2.8 (95% CI, 2.3 to 3.3) between six months and 8.6 
years  [130]. Paterson et al. reported on 20,290 patients that Charlson scores of 1 
correlated to increased risk of revision within 1 year, a hazard ratio of 2.1 (95% 
CI, 1.4 to 3.1). They could not find any risk increase for scores of 2 or above 
[131]. According to the Charlson score comorbidities have also been shown to 
increase the risk for infections [105], [107], [132], dislocations [87], early 
mortality, and adverse events within 90 days [13], [19], [88], [131]. 
Scores in relation to PROMs have been sparsely investigated. The Charlson 
score has been associated with poorer SF-36 results in the physical domain for 
590 patients [98]. Estimates using the questionnaire based on the Functional 
Comorbidity Index [133], with similar comorbidities to the Charlson score, 
indicate similar results for SF-36 outcomes 3, 10, and 16 years after surgery 
[134], [135]. 
1.2.3.2 Charnley class 
The Charnley classification was introduced in 1972 [47] as a comorbidity 
grouping for walking disabilities. It is today a widely recognized predictor for 
patient-reported outcomes after both total hip and knee replacements [93], 
[136]–[141], even though this has not been unanimously shown [90], [99], [142]. 
The classification has a simple design with 3 classes: 
A. One involved hip 
B. Two involved hips but no other joints 
C. Some other factor contributing to failure to achieve normal locomotion, 
such as rheumatoid arthritis, senility, hemiplegia, and cardiovascular or 
respiratory disability.  
Despite the simplicity there has been concern that the classification suffers from 
inter-observer variability [121], e.g. the class C reported by McGuigan et al. was 
around 4% [90] while Lavernia et al. reported 30% [142]. To complicate further, 
some split the B-class into 2 groups, those that have not operated the 
contralateral hip joint (B1) and those that have (B2) [138], [143]. These 
inconsistencies can cause difficulties when clinicians try to use the classification 
system to inform their patients.  
Self-administered classification as used for the nationwide follow-up program 
run by the SHAR may limit the interobserver variability. In the self-administered 
classification, Charnley class C is both common, 45% among patients eligible 
for THR, and a strong predictor for poor patient-reported outcomes [93]. 
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The Charnley classification has been sparsely investigated for mortality and re-
operation rates. Münger et al. reported on a large European case-control study on 
5,035 patients where patients with Charnley class B, i.e. a comorbidity 
suggesting less mobility and constituting one third of the sample, had fewer 
cases of aseptic loosening with an odds ratio of 0.8 (95% CI, 0.6 to 0.96). Class 
C did not show any risk reduction but these patients represented only 2% of the 
study sample [82]. 
Charnley classification is more frequently used together with PROMs. Rolfson et 
al. reported on a large nationwide sample that Charnley class A and B improved 
on average 0.38 while class C improved 0.35 on the HRQoL EQ-5D index, the 
corresponding improvement for pain VAS was 49 vs 46 mm [136]. For a disease 
specific instrument such as the Harris hip score the corresponding averages after 
5 years (90 patients) are 94 vs 78 points for [141], and after 13 years, 92 vs 72 
points [137]. 
1.2.3.3 Mental health 
Vissers et al. report in their systematic review that mental health negatively 
correlates to knee arthroplasty outcomes, but it is unclear for hip arthroplasty 
outcomes. For hip arthroplasties they summarized the evidence as limited, 
conflicting, or absent [144].  
Since then a few interesting studies have appeared. Stundner et al. studied 
1 million patients and found that depression and anxiety negatively impact 
hospital stay, higher cost, and non-routine discharge. Somewhat surprisingly 
they report lower odds for perioperative in-hospital mortality, odds ratio of 0.5 
(95% CI, 0.3 to 0.9) for patients with depression and 0.6 (95% CI, 0.4 to 0.9) for 
patients with anxiety [145]. Depression has also been associated with increased 
risk of periprosthetic joint infections, with hazard ratio 1.4 (95% CI, 1.1 to 1.7) 
[146]. 
1.2.3.4 BMI and obesity 
Obesity is a known risk factor for re-operations. The main concern for obese 
patients are periprosthetic joint infections. This has been shown to be especially 
true for the very obese
1
 with reported odds ratios ranging between 5 and 18 
[147]–[149]. It is possible that there is also a difference between the sexes and 
the impact of obesity; Lübbeke et al. found in 2,495 THRs that obese women, 
BMI ≥ 30, compared to obese men have been have a higher risk both for revision 
                                                 
1
 Super obese > 50 in the Malinzak et al. and  Everhart et al study, morbidly obese > 40 for the 
Jämsen et al. study 
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due to infection, relative risk 16 (95% CI, 3.4 to 76) vs 1.0 (95% CI, 0.2 to 5), 
and for revision due to dislocation, relative risk 3.0 (95% CI, 1.3, 7.1) vs 1.8 
(95% CI, 0.9, 3.6) [150]. A meta-analysis by Haverkamp et al. further added that 
obese patients had an increased risk of aseptic loosening and venous 
thromboembolism [151]. The loosening effect was also found by Münger et al. 
with an increase in odds ratio of 1.03 for every BMI unit (95% CI, 1.00 to 1.05) 
[82]. 
The data regarding PROMs and BMI are currently conflicting. Stevens et al. 
found in a larger retrospective study on 653 patients that BMI had a modestly 
negative influence on the WOMAC score and the SF-36 self-perceived general 
health subscale [119]. Similarly Davis et al found when studying 1,617 THRs 
that for every 10 points of BMI the Harris hip score decreased by 3.0% (95% CI, 
1.6 to 4.4) and all 8 SF-36 components except for mental health with effects 
ranging between 3 and 10% [152].  
On the other hand, Aranda Villalobos et al. looked at BMI > 28 kg/m
2
 and found 
in 70 prospectively recruited patients that the improvement for the WOMAC 
functional component and the SF-12 physical component was greater for obese 
patients [153]. Dowsey et al. in turn found no differences in 471 patients 
regarding improvement measured by Harris hip score or SF-12 when using 
WHO’ BMI categories [154]. Jones et al. found that there was increased pain at 
6 months but that the differences were negligible after 3 years for a mixed cohort 
of 520 hip and knee arthroplasties [155]. Studies with a 5-year follow-up support 
these Jones et al.’s results [150], [156]. 
1.2.3.5 Diabetes 
Diabetes is a known risk factor for infectious diseases [157] and especially 
uncontrolled hyperglycemia has been associated with surgical site infections 
[148], [158]. While some suggest that with modern techniques there is no 
increased risk for either deep or superficial wound infections [159], this is partly 
supported by Namba et al.’s finding that after adjusting for BMI the risk increase 
for diabetes disappeared [108], but few are ready to dismiss diabetes as a risk 
factor. Malinzak et al. found in a mixed hip and knee arthroplasty cohort of 
6,108 patients that patients with diabetes were 3 times as likely to suffer a 
periprosthetic joint infection compared to non-diabetic patients even after 
adjusting for BMI [147]. Pedersen et al. found an increased relative risk of 1.5 
(95% CI, 1.0 to 2.2) for revision due to periprosthetic joint infection within 2 
years of surgery although they did not adjust for BMI [160].  
Marchant et al. investigated a mixed hip and knee arthroplasty cohort of 1 
million patients comparing patients with uncontrolled diabetes (0.4%) and 
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controlled diabetes (10.2%) to those without diabetes, although data regarding 
BMI was not available in this analysis. They found that controlled diabetes was 
associated with urinary tract infections, odds ratio of 1.2 (95% CI, 1.2 to 1.3), 
while patients with uncontrolled diabetes had [161]:  
 Increased mortaliy: odds ratio 2.7 (95% CI, 1.7 to 4.4) 
 Cerebrovascular accident: odds ratio 4.1 (95% CI, 2.4 to 7.0) 
 Urinary tract infection: odds ratio 2.5 (95% CI, 2.0 to 3.0) 
 Ileus: odds ratio 2.5 (95% CI, 1.7 to 3.4) 
 Infection: odds ratio 2.3 (95% CI, 1.4 to 3.8) 
 Postoperative hemorrhage or shock: odds ratio 1.8 (95% CI, 1.3 to 2.6)  
Diabetes and PROMs have been sparsely investigated. Judge et al. report a small 
sample of 282 patients where they found that diabetes increased the risk of 
failure to improve after surgery according to a physical functioning score of the 
SF-36 instrument. However, this effect did not remain significant after adjusting 
for covariates [117]. 
1.2.3.6 Other diseases 
Queally et al. investigated the effect of neurological diseases and concluded that 
THR can have a good outcome among these patients [162]. Patients with 
Parkinson’s disease are commonly believed to have a higher dislocation rate due 
to their poor muscular control, although evidence is inconclusive. Meek et al. 
found in a large registry study on 14,314 THRs that the dislocation rates were 
not more frequent among patients with stroke or Parkinson’s disease [163]. 
Jämsen et al. found in a case-control study on 857 patients with Parkinson’s 
disease and 2,571 controls that patients with Parkinson’s have an increased risk 
for hip dislocations during the 1
st
 year, hazard ratio 2.3 (95% CI, 1.02 to 5.3) 
[164]. 
Bozic et al. recently reported on comorbidities and risk of revisions within 12 
months for 56,030 patients 65 years and above
1
. They found that out of 29 
comorbidity categories, 6 were associated with a higher risk of revision [165]: 
 Depression, hazard ratio 1.6 (95% CI, 1.4 to 1.9) 
 Rheumatologic disease, hazard ratio 1.3; 95% CI, 1.11–1.57) 
 Psychoses, hazard ratio 1.3 (95% CI, 1.1 to 1.7) 
 Renal disease, hazard ratio 1.3 (95% CI, 1.1 to 1.6) 
 Chronic urinary tract infection, hazard ratio 1.2 (95% CI, 1.01 to 1.3) 
                                                 
1
 The article does not state the surgery indication or the proportion of patients with primary 
osteoarthritis 
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 Congestive heart failure, hazard ratio 1.2 (95% CI, 1.01 to 1.4) 
The same group also studied 90-day mortality in 40,919 THR patients and found 
that neurological diseases such as dementia, hemiplegia or paraplegia, and 
cerebrovascular disease increase the risk estimates. They also found that 
congestive heart failure, metastatic cancer, psychosis, renal disease, and chronic 
pulmonary disease correlate with increased mortality rates [146]. Memtsoudis et 
al’s study on in-hospital mortality of almost 7 million procedures, in a mixed hip 
and knee arthroplasty cohort, confirms the findings that dementia, renal disease, 
and cerebrovascular disease are associated with increased risk of dying [8].  
Singh et al. investigated if heart disease, peripheral vascular disease, renal 
disease, chronic obstructive pulmonary disease, diabetes, or connective tissue 
disease increase the risk for persistent moderate/severe pain after 2 and 5 years. 
Out of the six comorbidities they found that peripheral vascular disease had an 
almost significant risk of higher odds ratio for moderate/severe pain after 2 
years, odds ratio 1.5 (95% CI, 1.0 to 2.4), and somewhat surprisingly renal 
disease was associated with a lower odds ratio, 0.6 (95% CI, 0.3 to 1.0) [166]. 
1.3 SUMMARY 
Patient characteristics impact the outcomes after THR. The impact is not 
universal between the different outcomes, i.e. some may improve implant 
survival while at the same time correlate with poorer PROMs. It is also highly 
likely that many comorbidities coexist in complex fashion, for instance there are 
well-established reciprocal links between depression and obesity [167], and 
obesity and diabetes [168]. This may partially explain why different studies vary 
regarding the estimates. Furthermore, there are more inconsistencies regarding 
PROMs than other outcomes and little seems to be known of the underlying 
mechanisms. Worth noting is that important patient characteristics such as 
smoking [169], educational status [100], [170], and alcohol consumption [33], 
[171] are beyond the scope of this thesis. 
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2 AIMS 
The overall aim of this thesis is to estimate the impact of common patient factors 
on outcomes after THR by using the Swedish Hip Arthroplasty Register, and 
cross-matching with other population-based registers. 
The specific aims of this thesis were to investigate: 
1. If comorbidity measures developed for mortality outcomes also are 
applicable for re-operations. 
2. How age influences health-related quality of life (HRQoL). 
3. If sex/age interacts with self-administered Charnley classification in 
regards to HRQoL. 
4. The generalizability of HRQOL estimates. 
5. If antidepressant use impacts patient-reported outcomes. 
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3 METHODS 
3.1 STUDY DESIGN 
All studies except study III are retrospective nation-wide cohort studies. Study 
III is a cross-sectional study as there is no pre-operative data. 
3.2 DATA SOURCES 
The five manuscripts included in this thesis are combined from five different 
data sources (Figure 1).  
 
 
Figure 2: The basis for the study datasets and the surgery years included 
3.2.1 The Swedish Hip Arthroplasty Register 
Since its inception in 1979 the Swedish Hip Arthroplasty Register has collected 
data on all primary THRs and their re-operations associated to the primary THR 
performed in Sweden [20]. The registry is the second oldest quality register in 
the world and includes 98% of all patients operated with a total hip arthroplasty 
from all Swedish hospitals [14]. Since 1992 the patient’s personal registration 
number has been collected, allowing follow-up that is patient and hip-specific. 
3.2.1.1 Patient-reported outcome measures 
In 2002 a program for gathering patient-reported outcome measures (PROMs) 
was adopted. The program reached full nation-wide coverage in 2008 [93]. A 
  17 
PROM questionnaire is presented to all elective THR patients pre-operatively 
and 1, 6, and 10 years after surgery. Each hospital is responsible for data 
collection and registration within an online database. 
3.2.2 The Swedish National Patient Register 
The Swedish National Patient Register was started in 1964 and includes all in-
patient care in Sweden since 1987 with discharge codes according to ICD-9 and 
ICD-10 and admission/discharge dates. It was previously known as the in-patient 
register but as of 2001 it also includes outpatients visits [172]. The proportion of 
patients with a given diagnoses where the registry code is deemed correct (the 
positive predictive value) is around 85-90% [173].  
3.2.3 The Prescribed Drug Register 
The Prescribed Drug Register (PDR) was initiated in July 2005 and includes any 
withdrawn prescriptions. Prescriptions that are never withdrawn by patients and 
drugs bought over the counter without prescriptions are not included. The data 
fields used were the drug ATC-code, number of pills, and prescription text  
[174]. 
3.2.4 The Danish study sample 
The Danish Hip Arthroplasty Register (DHR) has collected nation-wide samples 
from the Danish THR population on different PROMs. These include among 
other items the same HRQoL measure as used by the Swedish Hip Arthroplasty 
Register, the EQ-5D instrument [175]. 
3.3 PATIENT SELECTION 
3.3.1 Study I 
We included all patients operated between 1992 and 2007 that had received a 
THR due to primary osteoarthritis. Patients that had received a resurfacing 
arthroplasty or an implant used less than 500 times were excluded. 
3.3.2 Study II 
We included all patients operated between 2008 and 2010 with THR due to 
primary osteoarthritis. We only included patients above 40 years of age due to 
rarity of osteoarthritis prior to 40 years and the risk for indication 
misclassification.  
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Patients with re-operations or death within 1.5 years from index operation were 
excluded. If a patient had two records due to bilateral surgery, only the first hip 
with complete data was selected. 
3.3.3 Study III 
Similar to study II, we included all patients operated between 2008 and 2010 
with THR due to primary osteoarthritis above 40 years of age. We included only 
those that had filled out the pre-operative questionnaire. Patients with re-
operations or death within 1.5 years from index operation were excluded. If a 
patient had two records due to bilateral surgery, only the first hip with complete 
data was selected. We also excluded patients where the second surgery occurred 
prior to filling out the one-year PROMs questionnaire. 
3.3.4 Study IV 
We included from the SHAR all patients operated in 2006 and 2007, and from 
the DHR sample we included all patients operated in 2008 with complete one 
year EQ-5D. Patients re-operated within a year or with missing values in any of 
the outcome scores were excluded from the analysis. For bilateral cases, only the 
first operation with complete data was selected. 
3.3.5 Study V 
We included patients operated from July 2006 through December 2007. We 
included only those that had filled out the pre-operative form. If a patient had 
bilateral hip surgery within the observation period, only the first hip with 
complete data was included. Patients with re-operations within 1.5 years from 
index operation were excluded. 
3.4 OUTCOMES 
3.4.1 Study I 
In study I the outcome was re-operations between 0-2 years and 2-12 years. Re-
operation was defined as an open surgical procedure localized to the hip joint 
that could in some way be related to a previous THR, regardless of whether any 
of the parts or the entire implant was exchanged, removed, or left in situ. 
The time to event was defined as the period between the initial surgery and the 
day of re-operation, death or end of study period, whichever came first. 
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3.4.2 Study II to IV 
In studies II, III and IV, the outcome was HRQoL measured by the EQ-5D index 
and the EQ VAS 1 year after surgery. The EQ-5D form consists of 6 items, 5 
Likert questions and the EQ VAS. The questions span 5 dimensions of health: 
1. Mobility 
2. Self-care 
3. Usual activities 
4. Pain/discomfort 
5. Anxiety/depression.  
Each dimension has 3 levels of severity, generating a total of 243 combinations 
representing different health states. There are different value sets that may be 
used to translate these health states into a utility index.  
In studies II and III, we used the Swedish experience-based time-trade-off (TTO) 
value set to translate the answers into a score between 0.34 and 0.97; on a scale 0 
represents death and 0.97 maximum attainable HRQoL by the EQ-5D 
measurement [176]. As the Swedish tariff was published after study IV was 
published we used the Danish TTO tariff [177] for all patients, ranging from -
0.624 to 1. 
The EQ VAS, in turn, consists of a vertical VAS ranging from 0 to 100 where 
the patient is asked to mark their HRQoL and 100 corresponds to full health. 
3.4.3 Study V 
In study V we used HRQoL, pain VAS, and satisfaction VAS as outcome 
measures. HRQoL was measured as above using the Swedish tariff. The VASs 
for pain and satisfaction are similar to the EQ VAS with possible scores from 0 
to 100 on a horizontal scale. A score of 0 on the VAS pain scale corresponds to 
no pain. Similarly, complete satisfaction with the outcome of the operation 
corresponds to 0 on the satisfaction VAS. 
3.5 EXPOSURE VARIABLES 
3.5.1 Study I 
The exposure variables in study I were three different comorbidity measures 
calculated using ICD-codes from the NPR. All codes occurring during 
admissions 1 year prior to the surgery were included.  
Of the three measures, the Elixhauser score [128] is the most detailed with 30 
different categories; Charlson’s [127] consists of 19 categories, while Royal 
College of Surgeons (RCS) Charlson’s [129] has only 14 categories. There is, as 
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expected, a large overlap between categories in the three measures. The 
Elixhauser and the RCS Charlson score were calculated by counting 
comorbidities without any pre-assigned weights, i.e. a score of 2 indicates that 
the patient has 2 comorbidities as defined by that particular score. The Charlson 
score was calculated by applying the original weights and ranged between 1 and 
6, for instance myocardial infarction generates 1 point while metastatic cancer 
generates 6 points. All scores were grouped into three categories: 0, 1-2 and 
≥ 3 points. 
3.5.2 Study II 
The exposure in study II was age at time of surgery. Instead of modeling age as 
traditionally done by using categories or a linear variable, we used splines. The 
spline allows the line to bend according to predefined rules. This allows for a 
smooth relationship throughout the variable’s span, with minimal residual 
confounding [178].  
There are several different spline flavors, we used restricted cubic splines that 
use cubic terms in the center of the data and restrict the ends to a straight line; 
this helps to avoid the center distorting the ends. The flexibility of a spline is 
chosen by the number of knots, more knots allow a more detailed description of 
the relationship. To avoid overfitting the regression model by choosing too many 
knots, i.e. making the line too wiggly, the number of spline knots was chosen 
using the Bayesian information criterion (BIC) [80]. 
3.5.3 Study III 
In study III the exposure was the Charnley classification interaction with sex and 
age at surgery. In the PROM program, Charnley classification is assessed by the 
patient pre-operatively and at 1 year by using two questions:  
1) Do you have any symptoms from the other hip?  
2) Do you have problems walking because of other reasons (e.g., pain from other 
joints, back pain, angina, or any other medical condition impairing walking 
capacity)? 
3.5.4 Study IV 
The exposure was the patient’s country interaction with sex, age, and Charlson 
score. Charlson score was calculated as described in study I. 
3.5.5 Study V 
The exposure was withdrawal of antidepressants 1 year prior to surgery. 
Antidepressants were identified through ATC codes matching N06A in the PDR. 
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To avoid studying groups that received antidepressants for other conditions such 
as addiction, cancer, dementia, or Parkinson’s disease, patients taking any 
medication with ATC code N05A, N04, N06D, N03, N07B, N06AX12, or 
L02BA01 were excluded.  
Patients with suspected chronic pain syndrome were treated as a separate group 
and were not included in the antidepressant group, even if they received 
antidepressants. This group was identified by prescription text specifying chronic 
pain, pain syndrome, or prescriptions of Gabapentin (N03AX12), Pregabalin 
(N03AX16), or Tryptizol (N06AA09), where at least one of the prescription 
texts mentioned pain. Patients with Gabapentin or Pregabalin without the 
mention of pain were not included into the antidepressant group even if they also 
had antidepressant treatment. 
The antidepressant group was further subdivided into 4 groups according to 
prescription texts:  
1. Depressed: texts indicating depression and no mention of anxiety. 
2. Anxiety: texts indicating anxiety and no mention of depression. 
3. Mixed: texts with both depression and anxiety mentioned were 
categorized as a separate mixed group. 
4. Other/unknown: when there was no text indicating either depression or 
anxiety. 
In order to differentiate severity and stages of disease, 3 treatment types were 
identified: 
 Novel treatment, indicating non-chronic disease.  
Definition: no purchases during the first 6 months of observation. 
Patients with daily dispensed medications were considered novel if they 
had not received antidepressants the first 14 days. 
 Discontinued, possibly indicating less severe disease or poor adherence. 
Definition: no further antidepressant purchases occurred since an 
expected purchase. To limit the risk of drug hoarding the minimum time 
for discontinuation was set to 3 months. Patients with daily dispensed 
medications were considered discontinued if they had not received 
medication for 14 days. 
 Dose increase, possibly indicating a more severe disease. 
Definition: the daily milligram intake increased between prescriptions. 
Prescription text with escalating dosages were not included. 
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3.6 STATISTICS 
3.6.1 Survival analysis 
Re-operation rates were modeled using Cox proportional hazards [179], [180] in 
study I. The Cox proportional hazard model is a popular survival method that 
allows estimating individual parameters without knowing the baseline hazard. 
The method enables estimating the hazard ratio between different variables as a 
form of relative risk. 
3.6.1.1 Cox proportional hazards background 
The hazard h(tj) is defined as the j:th patient’s risk of experiencing an event, 
f(tj) = P(T = tj), if he/she has survived that far, S(tj) = P(T > tj-1) [181]. The P(…) 
denotes a probability ranging from 0 to 1. 
  (  )   (    |      )  
     
       
 ( 1) 
The Cox proportional hazard model states that an individual’s hazard function is: 
        
                    ( 2 ) 
Note that the h0(t) is outside the exponential function and independent of the 
individual’s variables, the x-parameters. If this assumption holds true, i.e. that the 
parameters do not affect the hazard over time, the estimates, the β-parameters, 
can be interpreted as hazard ratios. For instance if we have two individuals in a 
randomized controlled trial with two treatment arms, their functions would be: 
 
              
                   
                
                  
                   
             
( 3 ) 
If we want to compare their hazards, we see that the hazard ratio (HR) is 
independent of the h0(t): 
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( 4 ) 
3.6.1.2 Competing risk regression 
Since a dead patient can no longer be re-operated, death can be viewed as a 
possible competing risk to re-operation. The results were therefore validated 
using competing risk regression [181]–[184]. The competing risk regression is 
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similar to Cox proportional hazards regression with the important exception that 
it investigates the subhazard (denoted as  ̃   ) instead of the general hazard 
function. If all subhazard functions are summed they combine into the Cox 
regression model hazard function, h(t), i.e. for p number outcomes: 
      ∑ ̃    
 
   
 
∑      
 
   
    
 ( 5 ) 
3.6.1.3 Proportional hazards assumption 
The proportional hazards assumption was investigated using Schoenfeld 
residuals [185], [186]. These should align along a straight line for each estimate. 
If hazard ratios increase over time, the overall hazard ratio for the risk factor will 
be overestimated. Conversely, decreasing hazard ratios will lead to 
underestimation of overall hazard ratio [183]. 
3.6.1.4 C-statistic 
In order to provide an estimate for the scores’ ability to identify patients at risk 
of re-operations and to compare with the scores’ evaluation on mortality, we 
used the area under the ROC-curve for a logistic regression model. A value of 
0.5 indicates that a model does no better at identifying patients than pure chance, 
while a value of 1 would mean that the model manages to correctly identify all 
patients that are later re-operated. 
3.6.2 Linear regression 
For studies II to IV we used ordinary least square linear regression models. In the 
linear regression studies the mean and each estimate should be interpreted as that 
variable’s effect on the mean. The general form is written as: 
                    ( 6 ) 
This translates into matrix format where each patient is one row in the Y and X 
matrix and the β are the unknown estimates of interest: 
      ( 7 ) 
Estimating the β through the above formula gives: 
             =Hy ( 8 ) 
Explanation: The    indicates the X matrix transposed, i.e. flipped horizontally. 
By multiplying the transposed matrix with the original, a square matrix is 
generated. The benefit of the square matrix form is that it allows for calculating 
the inverse, the         part, and can thus be moved to the y side of the equal 
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sign, thus solving the equation for β. The complex           is often referred to 
as the ‘hat matrix’ (H) matrix since Hy gives the predicted values, the  ̂ where 
the ̂  (‘hat’) indicates that it is estimated and not the true value. The diagonal 
elements in this matrix relate to the impact that a particular observation has on 
the model, also referred to as the leverage. 
3.6.2.1 Interactions 
Interactions were investigated with multiplicative terms. For instance if a sex and 
Charnley class with three classes (A, B, C) interact, the model changes from: 
                      ( 9 ) 
To: 
                                              ( 10 ) 
Where the multiplicative term estimates were investigated through ANOVA-
testing the null hypothesis: 
                    ( 11 ) 
3.6.2.2 Heteroskedasticity 
In order to construct valid p-values and confidence interval, the linear regression 
needs to estimate the error for each estimate (β). As the studied outcomes were 
bounded, i.e. had a ceiling and a floor, we used robust covariance matrices in 
order to limit the impact of the heteroskedasticity on the model [187].  
Ordinary least square regression calculates the variance of the β through the 
residual errors. The residual error is the part that is not explained by the model, 
illustrated below by the ε:  
        ( 12 ) 
By extracting the ε we get: 
      ̂                    ( 13 ) 
By further separating the y we can simplify the formula: 
         
                  ( 14 ) 
The    is the identity matrix, a square matrix with n rows/columns containing 
only 0 except for the diagonal that contains 1. The identity matrix serves a 
similar purpose to the number 1 in regular mathematics. This equation illustrates 
the relationship between the H-matrix and the errors. 
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The variance for  ̂ is: 
    ( ̂)                             ̂         ( 15 ) 
Under Gauss-Markov assumptions the variance estimates for the  ̂ is  ̂    
whereby the above simplifies to: 
    ( ̂)          ̂         
∑   ̂
  
   
     
 ( 16 ) 
White [188] noted that under heteroskedasticity the errors will not simplify into a 
single  ̂ , and the more complex variance estimator formula ( 15 ) should be 
retained. He suggested that instead of the  ̂    for the  ̂, the squared errors for 
each row,  ̂         ̂
      ̂
  , give a better estimate. Together with 
MacKinnon he further expanded this into the HC3 method [189], that was later 
popularized by Long and Ervin’s method comparison [190]: 
  ̂       
  ̂
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The h in the formula originates from the diagonal elements on the H-matrix, see 
formula ( 14 ). By adding this to the denominator it elegantly inflates each 
element’s error to its actual impact on the model. This since the the h carries 
information about each observation’s leverage on the estimates (see above). 
3.6.2.3 Residuals 
If the residuals indicate a non-normal distribution, the model mean may be 
difficult to interpret. Non-normal distributed errors may also affect inference but 
with the large sample size this impact is limited due to the central limit theorem. 
The normality of the residuals was investigated through histograms and QQ-
plots. 
3.6.3 Quantile regression 
For study III we also used quantile regression [191] in order to study effects of 
Charnley classification on poorly performing patients. The quantile regression is 
similar to the linear regression with the exception that it studies different 
quantiles. Quantiles lack distribution assumptions and allow a more detailed 
study of a variable’s impact on the population.  
3.6.4 Non-linearity 
Throughout all studies we tried to avoid categorizing variables or refraining to 
simple linear relationships. By linear we mean that a continuous variable such as 
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age has the same impact between ages 40 and 41 as 80 and 81. We used non-
linear relationship as described in section 3.5.2. The non-linearity was evaluated 
by investigating the coefficients through ANOVA as was done for interactions 
(see section 3.6.2.1).  
In order to limit the risk of overfitting we controlled the flexibility of the splines 
using the Akaike Information Criterion (AIC) and the Baysian Information 
Criterion (BIC) [80, pp. 23–24, 202–203]. Smaller AIC and BIC indicate a better 
model. The AIC is defined as: 
            ̂  ( 18 ) 
Where k is the number of parameters in the model and L is the maximum 
likelihood for the given model. BIC is similar and can be approximated by the 
formula: 
                  ̂  ( 19 ) 
The n indicates the number of study subjects. Due to the large n in our studies 
the BIC will select simpler models than the AIC.  
3.6.5 Software 
All statistical computations were performed in R [192]. The statistical 
computations were performed using the rms-package [193], while the ggplot2 
[194] and Gmisc-package were used for graphical output. For reproducible 
research, dynamic documents were used together with the knitr-package [195]. 
SPSS combined with the Python-plug-in was used for extracting variables and 
cleaning data. Regular expressions [196] were used for text data mining.  
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4 RESULTS 
4.1 STUDY I 
4.1.1 Early re-operations 
We identified 134,423 total hip arthroplasties (114,072 patients) with primary 
osteoarthritis (Table 1). 1,826 (1.4%) arthroplasties had been re-operated within 
2 years. The two main reasons for early re-operations within 2 years were 
dislocations and infections. 
The risk for re-operation increased continuously in the RCS Charlson and 
Elixhauser scores (Figure 3). The Elixhauser score was the only measure where 
both comorbidity groups were significantly different from the healthy group, and 
it was least affected by the confounders. None of the score estimates showed 
significant changes when using only ICD-10 codes. The C-statistic for the best 
performing measure, the Elixhauser score, was 0.52 (95% CI, 0.51 to 0.53).  
We also compared the results with an unweighted Charlson score, and the 
difference in the estimates was negligible. The weighted van Walraven version 
of the Elixhauser score exhibited similar estimates to the unweighted score, 
although it lacked the continuous increase. 
4.1.2 Late re-operations 
From the original cohort 118,065 total hip arthroplasties had been observed for 
more than 2 years, average follow-up was 7.1 (SD: 3.2) years. In this group 
4,244 (3.6%) arthroplasties had been re-operated. The main reason for re-
operation in the later period was aseptic loosening, and the second most common 
reason was dislocation. 
In the period 2-12 years, none of the scores had any significant impact on the re-
operation rates. When we applied a non-weighted Charlson score the category ≥ 
3 had a close to significant estimate p = 0.053, hazard ratio of 1.9 (95% CI, 1.0 
to 3.7). This estimate also increased when looking at only patients with ICD-10 
codes, 2.6 (95% CI, 1.1 to 6.2). We also investigated the van Walraven version 
of the Elixhauser score, but it did not perform better than the unweighted score. 
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Variable 
0 - 2 years 
n = 134,423 
  
2 - 12 years 
n = 118,065 
  
No. of 
patients 
No. (%) of 
re-operations 
  
No. of 
patients 
No. (%) of 
re-operations 
Age 
  < 50 3,351 55 (1.6%)  3,006 273 (9.1%) 
  50 to 59 16,755 245 (1.5%)  15,148 979 (6.5%) 
  60 to 69 52,676 728 (1.4%)  46,317 1,158 (2.5%) 
  70 to 79 41,777 503 (1.2%)  37,121 1,659 (4.5%) 
  ≥ 80 19,864 295 (1.5%)  16,473 175 (1.1%) 
Sex 
  Female 77,134 897 (1.2%)  68,203 2,028 (3.0%) 
  Male 57,289 929 (1.6%)  49,862 2,216 (4.4%) 
No. surgery 
  First 112,032 1,487 (1.3%)  98,993 3,762 (3.8%) 
  Second 22,391 339 (1.5%)  19,072 482 (2.5%) 
Charlson score 
  0 119,427 1,572 (1.3%)  106,070 3,957 (3.7%) 
  1-2 13,914 235 (1.7%)  11,279 273 (2.4%) 
  ≥ 3 1,082 19 (1.8%)  716 14 (2.0%) 
RCS Charlson score  
  0 123,299 1,657 (1.3%)  109,334 4,035 (3.7%) 
  1-2 10,897 164 (1.5%)  8,583 206 (2.4%) 
  ≥ 3 227 5 (2.2%)  148 3 (2.0%) 
Elixhauser score 
  0 106,908 1,386 (1.3%)  95,896 3,665 (3.8%) 
  1-2 25,071 389 (1.6%)  20,399 546 (2.7%) 
  ≥ 3 2,444 51 (2.1%)  1,770 33 (1.9%) 
Type of prosthesis 
  Cemented 122,833 1,621 (1.3%)  108,642 3,626 (3.3%) 
  Uncemented 4,160 74 (1.8%)  3,167 194 (6.1%) 
  Hybrid 4,122 62 (1.5%)  3,904 397 (10.2%) 
  Rev. hybrid 3,308 69 (2.1%)  2,352 27 (1.1%) 
Hospital type 
  University hospital 15,598 197 (1.3%)  14,184 823 (5.8%) 
  County hospital 54,645 898 (1.6%)  48,096 1,821 (3.8%) 
  Rural hospital 55,590 618 (1.1%)  48,485 1,425 (2.9%) 
  Private hospital 8,590 113 (1.3%)  7,300 175 (2.4%) 
Table 1: Study population characteristics for study I 
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Figure 3: The different scores and their hazard ratios. All scores are fully adjusted for confounders. 
None of the scores’ hazard ratio estimates go above 2, and only the Elixhauser score indicates a 
continuous increase with increasing score. 
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4.1.3 Other analyses 
4.1.3.1 Sex 
Women had a lower re-operation rate for both the early and late period, hazard 
ratio of 0.7 (95% CI, 0.6 to 0.8) during the first period and 0.7(95% CI, 0.6 to 
0.7) in the later period. During both periods we observed a difference in the 
effect of implant fixation between the sexes. Women had a higher hazard ratio 
with all implants other than fully cemented, with the only exception for reverse 
hybrids in the later period. In men the choice of fixation had no certain influence 
during any of the periods. 
4.1.3.2 Age 
The age estimate changed considerably between the two time periods. In the 
early period, 0-2 years, the effect was negligible, while in the later period, 2-12 
years, the risk for reoperation decreased with increasing age (Figure 4). 
 
Figure 4: Adjusted estimate for age and risk for re-operation where the median age is the reference. 
The grey area at the bottom indicates the age distribution in the study population. 
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4.2 STUDY II 
We identified 27,245 patients during this period that had been operated due to 
primary osteoarthritis with complete data. The majority of patients improved 
according the both measures. For EQ VAS twice as many failed to improve 
compared to the EQ-5D index (16% vs 9%). This failure to improve increased in 
patients above 80 years of age; 20% of these elderly patients failed to improve 
their EQ VAS score and 13% failed to improve their EQ-5D index. However, 
only a minority (14%) of patients were above 80 years of age (Figure 5). 
 
 
 
Figure 5: Age distribution between the sexes and the proportion that fail to improve their HRQoL 
according to EQ-5D and EQ VAS. Darker colors indicate a larger proportion that fail to improve 1 
year after surgery compared to their pre-operative value. 
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4.2.1 Non-linearity of age 
The regression model confirmed that age was associated with a decrease in the 2 
HRQoL outcomes; a 40-year-old patient compared to an 80-year-old patient had 
on average a 0.030 higher gain in EQ-5D index (95% CI, 0.023 to 0.037) and a 
5.4 mm higher gain in EQ VAS (95% CI, 4.2 to 6.6). Furthermore the age-
related decrease was non-linear for both measurements, with a decrease that 
started in the patient's late sixties (Figure 6). The differences between patients 
below 70 years were minimal compared to patients above 70 years, the estimates 
for the EQ-5D index and the EQ VAS increased twofold for each decade after 70  
(Table 2).  
The dimensions that corresponded closest to the overall spline were mobility and 
usual activities. We found no support for interaction between age and sex for 
either outcome. 
 
Figure 6: The relation between the EQ-5D index and the EQ VAS 1 year postoperatively and the 
patient’s age at surgery. Pre-operative EQ-5D index and EQ VAS were set to the most frequently 
occurring values (Index = 0.87; VAS = 50) and are indicated by the horizontal dashed lines. The 
change before and after surgery is the height above this line, i.e. anything above is an improvement. 
The 2 lines differ only in height; the solid line with blue confidence interval indicates the optimal 
combination of covariates (male sex, first hip and Charnley class A) while the dotted line with pink 
confidence interval indicates the least favorable combination (female sex, previous contralateral hip 
surgery and Charnley class C). The pain VAS was set to the median, 65mm. 
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Age (years) Estimate 95% CI P-value 
EQ-5D index 
  40 vs. 70 years 0.011 0.003 - 0.018 0.004 
  50 vs. 70 years 0.009 0.004 - 0.013 < 0.001 
  60 vs. 70 years 0.007 0.005 - 0.009 < 0.001 
  70 vs. 70 years Ref. - - 
  80 vs. 70 years -0.019 -0.022 - -0.017 < 0.001 
  90 vs. 70 years -0.042 -0.048 - -0.037 < 0.001 
EQ VAS (mm) 
  40 vs. 70 years 1.2 -0.1 - 2.4 0.078 
  50 vs. 70 years 1.2 0.4 - 2.0 0.002 
  60 vs. 70 years 1.3 1.0 - 1.6 < 0.001 
  70 vs. 70 years Ref. - - 
  80 vs. 70 years -4.2 -4.7 - -3.8 < 0.001 
  90 vs. 70 years -9.3 -10.3 - -8.3 < 0.001 
Table 2: Age estimates with 70 years as reference 
4.2.2 Pre-operative HRQoL 
The pre-operative EQ-5D index and the EQ VAS explained substantially more 
than age; 3.9 times for the EQ-5D index and 1.9 times for the EQ VAS when 
comparing the variables’ impact on the model R-square value. Both pre-
operative HRQoL values exhibited a non-linear relationship with the 
postoperative value. Patients with low pre-operative values had the biggest gain, 
although they did not reach the same absolute levels. With increasing pre-
operative values the improvement lessens, and patients with pre-operative values 
close to the ceiling actually declined on average 1 year later.   
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4.3 STUDY III 
Complete data was available for analysis on 26,249 patients. Women were 
slightly older, experienced more pain, and categorized themselves more 
frequently in Charnley class C (Table 3).  
Women in Charnley class C had a poorer outcome than men (Figure 7). This 
interaction was strongest for the EQ-5D index, p-value for the EQ-5D index 
< 0.001 and for EQ VAS 0.0075. Age did not interact with Charnley class, p-
value for the EQ-5D index 0.57 and EQ VAS 0.30. 
 
Figure 7: An illustration of the different impact of Charnley class 
depending on sex. The red area indicates values below the pre-
operative index value. The dashed line indicates the predictions 
from a linear regression model while the solid lines depict quantile 
regression predictions at the different quantiles. 
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Variable 
Women 
(n = 16,322) 
Men 
(n = 12,263) 
Age (SD) 70 (± 10) 67 (± 10) 
Pain VAS (mm) 
  Mean (SD) 64 (± 16) 59 (± 16) 
  Missing 2 (0%) 5 (0%) 
Charnley class 
  A 7,145 (44%) 6,604 (54%) 
  B 1,788 (11%) 1,262 (10%) 
  C 7,387 (45%) 4,396 (36%) 
  Missing 2 (0%) 1 (0%) 
Previous contralateral THR 
  No 13,010 (80%) 10,102 (82%) 
  Yes 3,312 (20%) 2,161 (18%) 
HRQoL Estimates 
EQ-5D index (Pre-operative) 
  Mean (SD) 0.72 (± 0.12) 0.75 (± 0.11) 
  Missing 7 (0%) 8 (0%) 
EQ-5D index (1 yr) 
  Mean (SD) 0.87 (± 0.11) 0.89 (± 0.10) 
  Missing 1,292 (8%) 1,015 (8%) 
EQ VAS (Pre-operative) 
  Mean (SD) 52 (± 22) 58 (± 22) 
  Missing 14 (0%) 11 (0%) 
EQ VAS (1 yr) 
  Mean (SD) 75 (± 21) 78 (± 19) 
  Missing 1,294 (8%) 1,014 (8%) 
Table 3: Basic characteristics of study population, displaying the 
absolute numbers (%) for proportions and mean (± SD) of 
continuous variables. Missing is always presented as percentages for 
that particular group. 
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4.3.1 EuroQoL dimensions 
The sex interaction was mostly mediated by the mobility dimension where men 
in class C improved more frequently than women. 50% of men vs 40% of 
women improved at least 1 grade. The dimensions typically affected by the 
Charnley class were pain/discomfort and mobility. The pain/discomfort did not 
differ between class B and C, while both mobility and usual activities decreased 
with higher Charnley class.  
4.3.2 Grouping or subdividing the classification 
Each class of the Charnley classification had a unique impact on the HRQoL one 
year after surgery. The model with Charnley class A and B grouped had poorer 
BIC-estimates, indicating an inferior model. The Charnley classification’s 
contribution to the model improved by 12% for the EQ-5D index, and by 11% 
for the EQ VAS when we separated the A and B class. 
When analyzing the subdivision of class B, 3,156 patients were re-assigned to 
subclass B2 as they had according to SHAR previously operated the contralateral 
hip. Out of these, 2,749 patients were from class A and 407 patients from class 
B. While there was a considerable change between classes, the regression 
models did not improve by applying this knowledge; both the EQ-5D index and 
EQ VAS had poorer BIC with the split B class. 
4.3.3 Self-reporting 
Women reported Charnley class C more frequently than men both before (45% 
vs. 36%) and 1 year after surgery (47% vs. 37%). We also found a considerable 
change in reported class before and after surgery (Figure 8), 39% changed class. 
Crossovers that should be rare according to the original Charnley classification 
were fairly common, 18% changed either to class A from class B or C, or to 
class B from class C. The difference between men and women regarding 
crossovers was small, although women tended to a higher degree deteriorate to 
class C 1 year later. 
In the 1,284 patients that we excluded from the analysis due to contralateral 
surgery prior to reporting the 1 year follow-up form, class A was the least 
common class (6%). Class B was larger, approximately 4 times more frequent 
than in the studied population (46%), while the C-class proportion was similar to 
studied population (47%). 
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Figure 8: The crossover between Charnley classes from before to after surgery, the patients before 
surgery are on the left while those to the right are after surgery. Pink indicates the proportion of 
women in each group while blue corresponds to the proportion of men. The size of the arrow is 
proportional to the percentage of patients leaving that specific class, and the color of the gradient 
corresponds to the sex proportion for each transition according to the color bar. 
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4.4 STUDY IV 
We identified 14,560 patients from the SHPR registry and 632 patients from the 
Danish nation-wide sample. The Danish patients had an overall higher EQ-5D 
index and EQ VAS than Swedish patients (p-value < 0.001). Apart from this 
difference the two cohorts were similar.  
We found no difference between the countries in how sex, age or the Charlson 
comorbidity index affected the EQ-5D index (p-value = 0.83) or EQ VAS 
(p-value = 0.41) 1 year after hip replacement (Figure 9). 
 
 
Figure 9: Comparison of factors influencing EQ-5D index between Swedish and Danish patients. 
Forest plot with 95% confidence intervals for the estimates of EQ-5D index one year after THR for 
gender (reference=female), age 85 years (reference=65 years), and medium or high Charlson 
(reference=low Charlson) for Swedish (blue) and Danish (red) patients. 
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4.5 STUDY V 
We identified 10,700 patients that fulfilled our selection criteria. Up to 1 year 
before surgery, 9% of these patients acquired antidepressants at least once 
(n = 954). Of the patients treated with antidepressants, 51% had a prescription 
text indicating depression (n = 487), 3% indicated anxiety (n = 31), and 8% had 
text indicating both depression and anxiety (n = 75). Of the entire study 
population, 2% of patients (n = 177) were identified as being treated for a 
suspected pain syndrome with antidepressant medications.  
4.5.1 Antidepressant effect 
The use of antidepressants significantly decreased improvement in the EQ-5D 
index, EQ VAS, and pain 1 year after surgery after adjusting for gender, age, 
Charnley classification, pre-operative pain, pre-operative HRQoL, self-reported 
pre-operative anxiety/depression, pain treatment, and antidepressant (Table 4). 
Antidepressants did not affect satisfaction after surgery.  
Among the treatment types we identified 146 patients in the novel treatment 
group (15%), 150 patients in the discontinued group (16%), and 93 that had 
increased their dosage (10%). New and increased dosage of antidepressants 1 
year before surgery did not appear to influence any of the outcomes at one year. 
However, discontinuation of antidepressant usage was negatively associated with 
the patients’ pain and mildly associated with their satisfaction at 1 year (Table 5). 
The effect of treatment discontinuation on the pain outcome was also similar to 
those with a suspected pain syndrome (Table 4). 
4.5.2 EQ-5D anxiety/depression and antidepressants 
The prevalence of antidepressant usage increased with increasing severity in the 
EQ-5D anxiety/depression dimension: 5% for those patients that reported no 
anxiety/depression, 14% for those patients that moderate anxiety/depression, and 
26% for those patients that extreme anxiety/depression used antidepressant. 
There was no interaction between antidepressant use and the pre-operative 
anxiety/depression dimension, the smallest p-value identified was 0.1 for 
satisfaction (as measured by ANOVA).  
The majority (66%) of the patients reporting some form of anxiety/depression 
reported less anxiety/depression 1 year after surgery. This number was slightly 
lower among those treated with antidepressants (52%). While a few patients 
deteriorated in this dimension, those without any problems increased from 60% 
to 79% (Figure 10). 
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Figure 10: The crossover between anxiety/depression states from before to after surgery, the 
patients before surgery are on the left while those to the right are after surgery. The blue area 
indicates the proportion of patients with antidepressant treatment in each group and the missing 
are those that failed to return the follow-up form. Improvements are highlighted by green arrows 
while deteriorations by red arrows. The size of the arrow is proportional to the percentage of 
patients leaving that specific class. 
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4.5.3 Sensitivity analyses 
75% of the patients had at least 2 medication acquisitions up to 1 year before 
surgery (n = 711). The results were mostly unchanged when those with poor 
MPR were excluded (MPR < 0.8). Patients treated for depression, the most 
common indication, had also similar estimates to the overall group, although 
pain and satisfaction with THR 1 year after surgery were not significant. There 
was a slightly higher proportion of missing values among those receiving 
antidepressant treatments (p-value from Fisher's exact test = 0.068). The 
imputation resulted in the confidence intervals shrinking and discontinuation 
became significantly associated with satisfaction. 
 
  The EQ-5D index   The EQ VAS 
 
Estimate 95% CI   Estimate 95% CI 
EQ-5D Anxiety/depression dimension 
  None ref -   ref - 
  Moderate -0.038 -0.049 to -0.025   -4.5 -5.4 to -3.7 
  Extreme -0.075 -0.122 to -0.032   -9.8 -13.2 to -6.7 
Treatment with antidepressants 
  No ref -   ref - 
  Yes -0.042 -0.059 to -0.023   -3.0 -4.6 to -1.5 
Indication subgroups
a
 
  No treatment ref -   ref - 
  Depressed -0.039 -0.062 to -0.015   -4.7 -7.0 to -2.6 
  Anxious -0.005 -0.086 to 0.071   -2.6 -9.4 to 4.4 
  Both anxious and 
depressed 
-0.014 -0.083 to 0.046   0.1 -4.7 to 4.9 
  Unknown indication -0.050 -0.080 to -0.021   -1.5 -3.6 to 0.7 
Treatment change
b
 
  No change ref -   ref - 
  Novel treatment -0.003 -0.056 to 0.049   -1.0 -5.1 to 2.7 
  Dose increase -0.036 -0.112 to 0.034   0.2 -5.0 to 4.9 
  Discontinued 
treatment 
-0.004 -0.051 to 0.042   -2.9 -6.9 to 1.0 
Pain syndrome 
  No ref -   ref - 
  Yes -0.125 -0.169 to -0.081   -7.2 -10.4 to -3.9 
Table 4: Regression coefficients and 95% confidence intervals (CI) for health related 
quality of life outcomes. Negative estimates indicate poorer outcomes. 
a The indication subgroups use the same regression variables as the general model but has 
the diagnosis groups instead of the antidepressant variable.  
b The differences in treatment changes build on the general model with the addition of the 
treatment changes, i.e. the values are adjusted for the basic antidepressant treatment effect. 
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  Pain VAS   Satisfaction VAS 
 
Estimate 95% CI   Estimate 95% CI 
EQ-5D Anxiety/depression dimension 
  None ref -   ref - 
  Moderate 2.8 2.0 to 3.6   3.7 2.7 to 4.6 
  Extreme 4.7 1.8 to 7.7   6.1 2.9 to 9.6 
Treatment with antidepressants 
  No ref -   ref - 
  Yes 1.5 0.1 to 3.0   0.6 -0.9 to 2.3 
Indication subgroups
a
 
  No treatment ref -   ref - 
  Depressed 1.6 -0.5 to 3.6   1.5 -0.8 to 3.5 
  Anxious 2.5 -5.2 to 10.5   0.4 -7.3 to 10.0 
  Both anxious and 
depressed 
0.1 -4.4 to 4.8   -4.8 -8.5 to -0.8 
  Unknown indication 1.5 -0.8 to 3.8   0.5 -1.9 to 3.1 
Treatment change
b
 
  No change ref -   ref - 
  Novel treatment -1.4 -4.6 to 2.0   -3.2 -6.9 to 0.9 
  Dose increase 0.3 -4.0 to 4.8   1.8 -3.3 to 7.2 
  Discontinued 
treatment 
4.5 0.5 to 9   4.5 0.0 to 9.2 
Pain syndrome 
  No ref -   ref - 
  Yes 3.5 0.6 to 6.6   1.6 -1.7 to 5.0 
Table 5: Regression coefficients and 95% confidence intervals (CI) for pain and 
satisfaction. Positive estimates indicate poorer outcomes. 
a The indication subgroups use the same regression variables as the general model but has the 
diagnosis groups instead of the antidepressant variable.  
b The differences in treatment changes build on the general model with the addition of the 
treatment changes, i.e. the values are adjusted for the basic antidepressant treatment effect. 
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5 DISCUSSION 
5.1 STUDY I 
5.1.1 Discussion of results 
Of the three measures, the unweighted Elixhauser comorbidity score was closest 
to fulfilling the qualities that we sought after in the early period. In the late 
period none of the measures proved satisfactory.  
We believe that predicting arthroplasty outcome from comorbidities scores is 
more challenging than mortality. The C-statistic of 0.52 for the best score is far 
from the scores’ mortality models that range between 0.7 and 0.9 [197]–[199]. 
These results are cause for caution when interpreting comorbidity adjusted 
results, especially when the scores have not been validated for the studied 
outcome. 
The difficulty in predicting re-operations in the 2-12 year period is not 
surprising. One possible explanation is that comorbidities’ proximity in time 
may correlate to their impact, e.g. a cancer 10 years ago will have less impact 
than a cancer 1 year ago on a patient's risk of dying, and will probably also have 
less impact on re-operation rates. Beside this attenuation effect, the early and late 
periods exhibited different reasons for re-operations that may explain the lack of 
co-morbidity impact. It is also possible that severe comorbidities cause patients 
to use their hip less or die prior to any re-operation, thus having a protective 
effect. 
Bozic et al [146] looked at specific comorbidities in the Elixhausers score and 
infections after total hip arthroplasties. While they found rheumatologic disease, 
obesity, coagulopathy, and pre-operative anemia to be significant, none of these 
had a hazard ratio of more than 2. Surprisingly they failed to confirm previous 
findings of such common risk factors as diabetes [160], [161], [200]. Identifying 
universal risk factors seems to be a surprisingly difficult task. 
5.1.2 Strengths 
Our study’s main strengths are: a homogenous population, high quality of the 
data, and a large sample size. Choice of implant might be influenced by patient’s 
comorbidities [111], we believe therefore that it is vital to exclude rare, unproven 
implants, and to adjust for fixation type. By investigating only patients with 
primary osteoarthritis, and excluding rare implants, the population was ideal for 
evaluating the comorbidity measures’ impact. When studying comorbidities it is 
important that there is no residual confounding for the age variable. Age is 
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closely related to comorbidities and often regarded as the most important 
comorbidity measure. In this study we used a spline for age instead of age 
groups as commonly used [84], [88], [130], this minimizes residual confounding 
for age, and reduces the risk for measurement error or cut point bias[80]. 
5.1.3 Limitations 
We had no information concerning the technical outcome, patient compliance, or 
the surgeon’s experience. Although we stratified for type of hospital and volume, 
we lack detailed knowledge about the surgeon’s experience, a factor that is 
undoubtedly important [201]–[203].  
Another important limitation is that we probably failed to identify all co-
morbidities due to the crude nature of registry data. Although data from tertiary 
care or drug registry was not available during the study period, we believe that 
this detection bias is geared towards the less severe diseases. There is therefore 
reason to believe that the already weak associations would attenuate with 
inclusion of these undetected diseases. It is also noteworthy that the estimates 
were unchanged when we looked at the ICD-10 subgroup, although these 
patients were studied during a later period with higher prevalence of 
comorbidities. We interpret the increased prevalence of comorbidities in the later 
study period as due to improved diagnosis registration. This is due to the fact that 
a partly ICD-code-based funding was introduced in the 1990s, putting more 
emphasis on the patient’s comorbidities. This is supported by the Elixhauser 
score, with less severe comorbidity groups, that increased more than the other 
scores, while the age distribution remained unchanged during the study period. 
Patients with comorbidities might also be subjected to a surveillance bias. These 
patients may be more familiar with hospital settings and seek medical attention 
sooner, which affects the estimates. Although this effect is hard to rule out, we 
believe that the clinical problems subsequently leading to a re-operation bring 
the majority of patients to seek medical attention. 
In the study we looked at re-operation rates, and it is important to recognize that 
this is just one out of many possible outcome measures after total hip 
arthroplasties. Other outcomes such as quality of life, non-surgically treated 
infections or dislocations, or early re-admissions (e.g., due to pulmonary 
embolism and cardiovascular disease), are also important and require separate 
validation. It also important to note that re-operation is a wider definition of 
failure than revision. Although revision does not include hip-related surgery that 
leaves the implant untouched, previous studies with this outcome [88], [130], 
[204] have found similar estimates for the Charlson score. This strengthens the 
external validity of our findings. 
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We constructed the Elixhauser comorbidity score by counting disease categories. 
Elixhauser et al questioned this approach [128] since the impact of disease 
categories may vary between different outcomes. We believe that using a score 
instead of enumerating all the 30 comorbidities decreases the risk of overfitting 
the model. We also investigated an alternative weighted Elixhauser score, as 
suggested by van Walraven et al [198], but it did not outperform the unweighted 
score. Combined with the similarity of the different Charlson scores there may 
be a lack of difference between weighted and unweighted scores. It is possible 
that this could be due to a surgeon coding bias; a more difficult patient will 
probably have a more rigorous work-up, and thus also a more complete coding 
of the comorbidities. 
5.2 STUDY II 
5.2.1 Discussion of results 
We found a non-linear correlation between age and HRQoL 1 year after surgery. 
Both scores remained largely unaffected by age until a downturn in the patient’s 
late sixties. It is worth noting that increased age was correlated with lower pre-
operative HRQoL, as lower pre-operative HRQoL corresponded to a greater 
improvement, the majority of the elderly increasing in HRQoL 1 year after 
surgery.  
Since the mean age for surgery in this cohort was 69 years, one could argue that 
surgery is performed too late in order to maximize HRQoL outcome. On the 
other hand, the decline in improvement may be due to natural age-related 
deterioration of HRQoL that is not hip related, therefore it is expected that the 
intervention may have a smaller impact on the gained HRQoL in the elderly. 
HRQoL is also just one out of many possible PROM outcomes after THR, and 
while it is an interesting metric it should be combined with other measures 
during patient consultation [93]. 
Our results are in line with other large cohort studies. Pennington et al. reported 
that within 30,203 patients age correlated with a decrease in the EQ-5D index 
[205]. Judge et al. showed that for 1,375 THR patients, whose age was 
categorized into < 50, 50 to 60 and > 60 years, both the younger and elder 
categories performed worse according to the Oxford Hip Score. They concluded 
that age had a non-linear effect, but failed to explore the relationship further 
[206]. Cushnaghan et al showed in a small sample of 278 patients with THR that 
the SF-36 score was poorer in subjects above 67 when surveyed eight years after 
surgery [207]. It is not surprising that many studies have failed to detect the 
correlation for HRQoL outcomes [97], [98], [208], as the age variable only 
explained a minor part of the variation. Our data suggest that adjusting for age 
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above 70 years will mitigate confounding. While not recommended, ignoring 
age prior to 70 years can be a viable alternative in those situations where splines 
are difficult to implement. 
In addition to non-linearity for age, both the pre-operative EQ-5D index and the 
EQ-VAS exhibited non-linearity. Using the difference between the preoperative 
and the postoperative values, as many previous studies have done [93], [209], 
will lead to residual confounding as it assumes both linearity and that the 
preoperative HRQoL estimate equals 1. In these instances, the pre-operative 
HRQoL state carries some unadjusted information, and therefore, residual 
information in this variable. Furthermore, the figures demonstrate the 
instrument’s ceiling effect. When patients begin with a high HRQoL close to the 
ceiling, they will on average deteriorate as any improvement cannot be measured 
beyond the instrument’s ceiling. This can also be viewed as a regression to the 
mean where extreme observations tend to move toward the population mean.  
5.2.2 Strengths 
The main strength of our study is the nation-wide population and should 
therefore be representative of the common patient. The small difference between 
respondents and non-respondents at the 1 year follow-up also supports our belief 
that the results are generalizable.  
Another important strength is that we used splines instead of categorization. 
Categorizing continuous variables introduces a cut point bias [210], [211]. 
Identifying the best divisor between groups by optimizing cut points can increase 
the risk for type I errors. For instance, a study that reports a p-value of 0.05 and 
that has applied optimal cut points should in reality be reporting a p-value > 0.25 
[212]–[215]. If standard cut points or quantiles are used instead of optimal cut 
points, this usually results in a loss of power. For instance, dichotomizing a 
normally distributed continuous variable can be equivalent to reducing the study 
population by a third [216]. While these properties are well known among 
statisticians, we have found no clinical articles that implemented splines to 
model age for HRQoL outcomes. 
5.2.3 Limitations 
Our study is limited by the small amount of data per patient. Expanding the 
routine follow-up program with more questions to provide more detailed 
background information may enhance the regression model but it will jeopardize 
response rates, thus hurting the generalizability. The follow-up is also only 1 
year after surgery; however previous studies have shown surprisingly little 
change beyond 1 year [206], and the mid-term HRQoL seem consistent [217]. 
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It is important to remember that we looked at the chronological age, not the 
biological age. Using a biological marker for age may improve the accuracy of 
the model as the life span of humans is heterogeneous [218]. This is outside the 
scope of a registry study but may be plausible in a smaller study. Similarly, if a 
more detailed co-morbidity adjustment than the Charnley classification was 
applied, the effect of age may be further attenuated and even more difficult to 
detect.  
5.3 STUDY III 
5.3.1 Discussion of results 
We show that Charnley class B is an independent risk factor and should not be 
grouped with class A. Furthermore the patient-reported Charnley class B does 
not benefit from subdivision when assessing HRQoL [138], [143].  
There is also a sex difference in Charnley class C’s impact for on the EQ-5D 
index between men and women, where women gained less than men. The 
mobility dimension seemed to be the main cause behind this interaction, where 
25% more men than women improved 1 year after surgery. A possible 
explanation may be that Charnley class is closely correlated to postoperative 
ambulation [219], and that women have a different rehabilitation pattern [220]. It 
is also conceivable that women interpret class C differently, i.e. that the men in 
class C and women in class C are not comparable. As almost half of all women 
belonged to Charnley class C we believe that this is an interesting sub-population 
to further study. 
Interestingly, sex differences were not seen for the EQ VAS outcome, possibly 
due to a different impact of mobility on HRQoL between the sexes. Furthermore, 
this difference between the EQ-5D and the EQ VAS illustrates how the 5 
dimensions can capture different qualities than the EQ VAS, adding value to the 
overall patient understanding.  
The Charnley classification intends to categorize patients according to their 
walking ability and contralateral hip disease. Consistent with this intention, the 
mobility and pain/discomfort dimensions in the EQ-5D index were the 
dimensions most affected by the self-categorized Charnley classification. 
Perhaps less consistent with the intention was the sizeable change between the 
pre-operative Charnley class and the class 1 year later. Worth noting is that a 
considerable group crossed over into class A from both the B and C classes, 
suggesting that classification based on a patient-administered questionnaire is 
less rigid than the original intention [47]. Conversely, patients did seem to 
classify themselves correctly since those who had their contralateral hip operated 
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soon after rarely reported class A. This is further supported by the lack of 
improvement when subdividing the B-class according to prior hip arthroplasties. 
Interestingly, the few patients with a contralateral THR who reported class B, 
performed worse even after adjusting for pain and pre-operative HRQoL. This 
could both be due to fear of surgery or genetic predisposal to postoperative pain 
[221]. We conclude that even though there is a difference from the original 
intention, patients seem to have a good understanding of their physical health, 
thus possibly explaining why this self-categorized Charnley classification is such 
a strong predictor. 
To our knowledge, no other large cohort studies on Charnley classification go 
into the details of the classification’s impact on HRQoL. In order to keep our 
message simple we did not investigate other important metrics such as pain and 
satisfaction that also are included by SHAR’s PROM program. Generic 
measures such as the EQ-5D index are interesting metrics as they combine many 
dimensions of health. While these measures are not as sensitive as disease 
specific measures [139], they do contain common osteoarthritis characteristics 
such as pain, activity of daily life, and mobility, while at the same time retaining 
the option of detecting unexpected correlations in other dimensions such as 
anxiety and depression. In large cohort studies, the study group size compensates 
for the lack of sensitivity, while preserving the ability to detect unexpected 
correlations.  
The estimated outcomes 1 year after surgery for different Charnley classes 
suggests that some patients will end up with values lower than their pre-
operative level. This estimation applies to the average-aged patient with the most 
common pre-operative health state according to EQ-5D/EQ VAS. Shifting the 
references to a lower pre-operative EQ-5D index/EQ VAS or to younger patients 
would decrease the risk of not improving. We chose this presentation of 
combined estimates instead of single estimates to better illustrate different 
quantiles. 
5.3.2 Strengths 
The main strength of our study is the large nationwide cohort with a good 
response rate to the survey and small differences between respondents and non-
respondents. We believe that the selected cohort is representative, while 
minimizing confounders such as early reoperations, recall bias due to 
contralateral surgery, and misclassification of surgery indication.  
We chose in this study to exclude those that died within 1.5 years. We believe 
that HRQoL is interesting only if a patient survives and can benefit from the 
gained HRQoL. Furthermore if a patient in Charnley class C is advised not to go 
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through with surgery both due to risk of dying and poor HRQoL outcome, there 
will in a sense be a double penalty. 
5.3.3 Limitations 
Our main limitation is the scarcity of information per patient. The registry has 
during this period started collecting interesting confounders such as BMI and 
ASA class. In future studies these will most likely be included in the models. 
The Charnley classification can also be strongly influenced by simultaneous 
knee osteoarthritis and other lower extremity disabilities that we have not been 
able to adjust for.  
5.4 STUDY IV 
5.4.1 Discussion of results 
We found no significant differences between Denmark and Sweden in how age, 
sex and comorbidity status influence the level of HRQoL 1 year after surgery. 
The consistency of these common and basic predictors facilitates pooling and 
comparisons between the two countries.  
There may be multiple explanations for Danish patients who report higher 
HRQoL 1 year postoperatively than Swedish. First, population studies have 
shown that Danish people in general perceive their HRQoL to be higher than 
Swedes do [222], [223]. Assuming the EQ-5D values for Danish patients are 
generally higher than for Swedish patients, this would partly explain the 
observed difference among the THR population. Second, differences in fixation 
method, implants used, and surgical technique may play a role for the PROMs. 
For instance, the posterior approach is more common in Denmark, and previous 
work indicates that a posterior approach is associated with better PROMs 
compared to the direct lateral approach [224], [225]. Third, the difference in 
mean age at surgery indicates that Danish patients have surgery at an earlier 
stage of hip disease. Although age is included in the regression model, there may 
be residual confounding due to age being a proxy for stage of hip disease. 
Surgery at an earlier stage of disease implies a preservation of HRQoL after hip 
replacement. Conversely, surgery at a late stage of disease may reduce the 
possibility of reaching the expected level of HRQoL for the particular age group 
5.4.2 Strengths 
The large study population that combines a nationwide Swedish THR population 
and a randomly selected nationwide Danish THR population contributes to the 
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strength of this study. Reoperations have been excluded, which limits the effect 
of potential confounders related to implant survival.  
5.4.3 Limitations 
The cross-sectional nature of the study limits comparisons of outcomes between 
the two countries, and only a limited set of variables have been included in the 
models. Pre-operative PROMs were not available for the Danish patients and 
thus comparisons taking baseline levels into account were not possible. 
Furthermore, the Danish population was much smaller than the Swedish and 
chance may affect Danish data to a greater extent than Swedish. Including a 
larger Danish population may result in significant differences between countries 
in how the investigated predictors affect the outcomes. However, the clinical 
relevance of such small differences can be questioned. 
It is also plausible that some of the differences come from the minor difference 
in recruited years. The consistency in the EQ-5D index over time in the Swedish 
THR population suggests though that this effect should be negligible. 
5.5 STUDY V 
5.5.1 Discussion of results 
Our analyses found that the use of antidepressants for depression significantly 
diminished pain reduction, inhibited improvement in HRQoL, and negatively 
influenced THR. In this study population, the antidepressant users were worse 
off before and 1 year after THR. Patients receiving pharmacological treatment 
for depression or pain syndrome with antidepressant medications perceived their 
overall HRQoL and pain to improve less than the other group. 
Somewhat unexpected, the influence of antidepressants on outcomes was 
independent of the response to the anxiety/depression dimension of the pre-
operative EQ-5D questionnaire. The lack of interaction between the 
anxiety/depression dimension and treatment is noteworthy, i.e. a patient that 
reported no anxiety/depression (responding to the treatment) does not differ from 
one who reports anxiety depression. This could possibly relate to the concerns 
regarding loss of antidepressant efficacy over the last decades, where the file 
drawer effect, i.e. negative studies go unpublished, and widening of indications 
may be part of the explanation [226]. The widening of indications is partly 
supported by the six-fold rise in sale of antidepressants in Sweden 1990 to 2002 
[227]. Despite this increase, studies have found that only one in four of with 
depression requiring treatment actually receive antidepressants [228]. This 
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proportion is similar to the treatment prevalence among the patients reporting 
extreme problems in the EQ-5D anxiety/depression dimension. 
The large improvement in the anxiety/depression dimension suggests that many 
patients were experiencing pre-operative anxiety. The smaller improvement 
among the patients treated with antidepressants supports this notion. 
Duivenvoorden et al. have reported similar improvement rates using the Hospital 
Anxiety and Depression Scale [229]. As pre-operative anxiety may respond to 
patient education [230] there may be room for improvement regarding this 
parameter, although Hossain et al. could not find any decrease in satisfaction 
related to pre-operative distress in 448 THR patients [231]. 
We also found that discontinuation of antidepressant treatment had a negative 
influence on pain and satisfaction. The effect size was similar to the group with 
pain syndrome. Interestingly, discontinuation of treatment was the only 
treatment change which influenced any of the outcomes. To our knowledge, this 
has never been shown and can have direct clinical implications; simultaneous 
discontinuation of antidepressant treatment in conjunction with major surgery 
may be unwise. 
A possible explanation for the depression effect could be the pain-depression 
link. Depression in patients with primary osteoarthritis has been correlated with 
sensitivity to pain and decreased ability to cope with the disease [232]. 
Depression is also known to be a catalyzer of pain, and addressing it early seems 
to improve outcomes [233], [234]. Because depressive disorders are common in 
patients with chronic pain, education about continued activity should be 
considered not only as a non-surgical treatment for primary osteoarthritis, but 
also as a preventative measure against the development of depression [235].  
5.5.2 Strengths 
The strength of this study stems from the use of the nation-wide register of 
primary osteoarthritis patients receiving THR. In conjunction with the nation-
wide register of prescription drug purchases, we were able to create a 
homogenous study population that excluded important confounding groups. 
Specialized code allowed the identification of various stages and severity of 
disease for patients taking antidepressant medications. Finally, rigorous 
validation minimized the risk of invalid data. 
5.5.3 Limitations 
A limitation of this investigation was that the indication for the antidepressant 
medications in 37% of the patients could not be identified. These patients were 
simply classified as users of antidepressants, but the indication was unknown. A 
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review of a Swedish subpopulation found that antidepressants were primarily 
prescribed for depression (66%), followed by anxiety (14%), and treatment of 
pain (11%) [236].  
Another limitation is that we cannot know with certainty whether patients took 
their prescribed medication. However, there is strong indication that the majority 
of patients were following the treatment set by their physician because they 
obtained their prescribed medication at least twice during the observation period. 
The variety of clinical indications for antidepressant prescription and the 
unknown compliance with treatment may limit our understanding of how 
psychological distress truly influenced PROMs in this population. Nevertheless, 
the majority of the antidepressant patients were clinically diagnosed with 
specific psychological conditions, and these conditions influenced PROMs after 
surgery.  
The aim of this study was to explore pre-operative factors associated with poor 
patient outcomes, for this reason we did not explore the novel, continued, or 
discontinued use of antidepressants after surgery. Future studies that focus on 
these postoperative factors will inform how antidepressant treatment continues to 
influence PROMs after surgery. 
5.6 GENERAL DISCUSSION 
5.6.1 Data quality 
All studies in this thesis are based upon the data in the Swedish Hip Arthroplasty 
Register. The register is renowned for its high data quality with a 100% of 
hospital coverage and a completeness of individuals about 98% for THR [14]. 
Primary operations are registered using a decentralized structure where each 
department enters the data. Data capture for reoperations is centralized, all 
medical records regarding the reoperations are sent to trained coordinators at the 
SHPR who then enter these into the database. Every year each department is also 
sent a list of primary and secondary interventions in order to review and report 
back any inconsistencies. 
Since the start improvements in quality have been continuously put in place. 
Söderman et al identified 10% of missing revisions in which 2 hospitals 
constituted almost half of the missing data [237], and since 2007 an annual 
quality control is performed by cross-matching data with the NPR. As of 2013 
there is also a monitoring system in which departments are visited by 
coordinators that compare the register data against the medical records. 
Even with this control we recently found that one third of all re-operations due to 
infection were missing [23]. There is also an ongoing investigation regarding 
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periprosthetic fractures due to concerns that fractures of Vancouver type A and C 
are underreported [25]. This lack of reporting could primarily affect the results in 
study I with falsely low estimates. The effect is probably most relevant for early, 
acute re-operations, as they are frequently managed by multiple surgeons during 
non-office hours.  
The PROM program has a pre- and postoperative response rate of around 80-
90% [93]. It is currently based upon pen and paper forms that are later filled in 
by secretaries at different clinics. It is possible that this causes some faulty data 
input causing a non-differential misclassification bias, most likely diminishing 
the estimates [238]. Efforts into digitalizing the program using web-based 
questionnaires were abandoned due to low response rates [239].  While the 
completeness is less than for re-operations, we have found little difference in the 
PROM results when applying multiple imputations. 
Similarly, the NPR has a high sensitivity and specificity for primary diagnoses 
[173], and combined with the Swedish personal identity number [240] the 
matching error between the registers is negligible. The misclassification bias is 
generally believed to be below 10% [241]. While primary ICD-codes are 
commonly correct, there may be less specificity among the secondary ICD-
codes. This is supported by the increase in comorbidities throughout the study 
period seen in study I. We believe that the increase in registration is mostly due 
to monetary incentives for registering as the age distribution for the population 
has not changed over the period. This possible detection bias may weaken the 
estimates from study I and IV, although the ICD-10 subgroup analysis in study I 
showed only small differences. 
The data capture for the PDR is fully automated by the pharmacies, and missing 
data should therefore be negligible. While there are no antidepressants currently 
sold over-the-counter, missing data in study IV can still theoretically occur from 
herbal products [242] or medications used in hospitals or from nursing home 
drug storerooms [243]. 
5.6.2 Code quality 
Equally important to data quality is the code quality. The Python scripts that 
extracted many of the variables for this thesis amount to 5,199 lines of code 
(289,955 bytes). Coding errors are inevitable, depend on code complexity, and 
are estimated by some to be around 10 per 1,000 lines of code [244]. As the 
effects of coding errors can be devastating, all code used in the thesis has been 
subjected to both white and black box testing [245].  
White box testing uses knowledge of the software’s design in order to test its 
different components. This was deployed for the comorbidity counts where unit 
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tests used the previously published SAS-code as a template. For the R-packages 
unit tests were deployed through the standard testthat-package [246].  
Black box testing is the opposite of white box testing in which no knowledge of 
the software design is used. The black box tests were performed using small 
random subsets of the original data. The results were then manually validated in 
order to find any unexpected bugs. The black box validation in study IV, the 
study with the most intense coding, was performed by Kristina Annerbrink in 
order to avoid creator bias.  
While few studies actively report their coding quality strategies, these are a 
source of study errors. In macro-economics the raw data is often available and 
the recent debacle regarding Reinhart and Rogoff’s famous optimal debt to gross 
domestic product (GDP) ratio [247] verifies this notion. The lack of code 
transparency has been noted in the statistical community [248] and this is also 
why we have openly published the central portion of the code used in this thesis 
on gforge.se.  
5.6.3 Patient selection 
Due to lack of detailed patient knowledge we have tried to select patient cohorts 
as clean as possible in each study. In study I we excluded rare implants in order 
to limit the risk of patients participating in implant studies. The Australian 
registry showed that none out of 167 new hip implants performed better than the 
old, and almost one third had a higher revision rate [38]. Thus it is highly likely 
that small series of implants, often restricted to studies, will perform worse. As 
studies frequently exclude patients with multiple comorbidities, this can be 
viewed as a form of confounding by indication [249].  
In study II-V we excluded patients that had an early re-operation or death. There 
is a high probability that motivation for reporting differs in these groups, patients 
may be too sick to report, experience a general resignation towards health-care, 
frustration, and other feelings not intended to be captured by the HRQoL-form. 
There is also a risk that including these would result in a sense of double penalty 
for the patients at increased risk for re-operations or death. 
5.6.4 Minimal clinically important difference 
As register studies contain thousands of patients, small differences with little 
clinical relevance may reach statistical significance. For re-operations, risk 
differences of 3% are often considered clinically relevant [104] but for PROMs 
the interpretation is less obvious. 
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 Jaeshke et al [250] defined minimal clinically important difference (MCID) as: 
“… the smallest difference in score in the domain of interest which patients 
perceive as beneficial and which would mandate, in the absence of 
troublesome side effects and excessive cost, a change in the patient's 
management” 
The MCID is a tool for clinicians to discern what treatment effects should 
encourage them to change their practice. Some differentiate between the 
minimally important distance (MID) and MCID [251] but for this discussion 
they will be used interchangeably. There are currently 2 main methodologies for 
estimating the MCID: distribution based methods and anchor based methods. 
5.6.4.1 Distribution based methods 
The general idea for distribution based 
methods is that the variance in the 
measurement relates to the MCID. 
Norman et al looked at 6 different MCID-
studies and noted that the MCID 
frequently coincides with one half of the 
standard deviation (SD). They therefore 
suggested that this may be an alternative 
metric when no established MCID exists 
[252]. 
A more theoretical approach is to use the 
standard error of measurement (SEM); this 
is the error that an individual makes when 
re-estimating his/her status according to 
the current outcome. Wyrwich et al found 
that 1 SEM frequently corresponds to the 
MCID [253].  
Both tools relate to the stability of the 
measurements, and suggest that a poor, unreliable instrument would demand a 
higher MCID than an accurate one. This can be viewed as if an observer were to 
identify a difference; the improvement needs to be larger than the noise. This 
further suggests that the MCID is the same no matter the intervention. If the 
intervention improves a patient’s well-being in a way similar to the 
measurement’s design, this may be reasonable. Conversely, if the measurement’s 
design is not tailored to the intervention, this assumption is flawed (Figure 11). 
HRQoL is arguably not tailored to measuring THR outcomes, and using the 
distribution of the measurement would therefore not be a sensible option. 
Figure 11: The two effect arrows are exactly the 
same length and the measurement size depends 
on the similarity between the effect and the 
measurement. Effect 1 indicates a larger 
similarity and thus its measurement will appear 
larger than effect 2. 
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5.6.4.2 The anchor based method 
Anchor based methods are currently the gold standard for deciding the MCID for 
a measurement [254]. The anchor refers to an external criterion that defines 
success for the intervention, e.g. patient’s experience of improvement or ability 
to return to work. By comparing the success group with the other, an estimate of 
the MCID can be attained. 
The patient’s experience is most commonly applied where a global rating of 
change (GRoC) scale is applied [255]. A GRoC scale contains a sequence of 
questions that aims to separate patients that have done worse from those who 
have improved. The questions are ordered and can range from 3 to 101 
alternatives. A simple 5-alternative GRoC scale could be [256]: 
1. Got a lot better 
2. Got a little bit better 
3. Unchanged 
4. Got a little worse  
5. Got a lot worse 
The MCID from the scale above would be the difference between the 3
rd
 and the 
2
nd
 group. Note that the difference between the 4
th
 and the 3
rd
 group above is 
likely different than the one between the 3
rd
 and the 2
nd
 group. 
There is currently no consensus on choosing the number of groups in a GRoC 
scale and which ones should be compared [254]. Preston and Colman showed 
that a test with 101 categories has reasonable reliability [257], although the large 
number may lead to answers of poorer quality [258]. Preston and Colman also 
suggested that about 10 alternatives are optimal. Note that depending on the 
number of groups, the distance between neighboring ones differs, thus a GRoC 
scale with more groups will generate smaller MCIDs. 
Walters and Brazier [259] compared MCIDs for the EQ-5D with the SF-6D 
index for 8 different cohorts. They used a 5-level GRoC scale where they 
compared those that performed slightly better to those that performed slightly 
worse. Apart from concluding that the MCID was different for the EQ-5D and 
the SF-6D indices, they found a large variety between different patient cohorts, 
e.g. MCID for the EQ-5D index in the knee osteoarthritis was 0.1 while in 
chronic obstructive pulmonary disease it was 0.0. The measurement and 
similarity of effect seem thus also to affect the MCID for anchor based methods 
(Figure 11). 
Kerujente et al. reported recently results for SF-36 after joint arthroplasties using 
an alternative anchor method; by asking patients if they would be willing to 
undergo surgery again, they could compare patient’s estimates and deduce a 
clinically important difference [94]. Although this is an interesting approach, it 
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does not truly estimate the minimal value. It seems also quite likely that patients 
will suffer from a recall bias perhaps larger than a satisfaction anchor. As the 
authors state, the main benefit with this approach is that it is difficult to identify 
patients for successful interventions such as arthroplasties who are only modestly 
satisfied, i.e. almost everyone will reply very satisfied, and the answer of interest 
for the MCID calculation will be rare, requiring very large cohorts. 
5.6.4.3  Risk and MCID 
Apart from MCID being dependent on diagnoses, it also most likely relates to 
the intervention risk. Estimating the MCID for patients going through with a 
THR may be affected both by high-risk high-demand and an IKEA effect bias 
[260], where the proudness of patients accomplishment, going through with the 
surgery and the intense rehab, cause them to overestimate their improvement, i.e. 
pushing the MCID downwards. In addition, the high-risk high-demand bias may 
cause patients to expect a large improvement as the risk associated with surgery 
is perceived to be high, thus pushing for higher MCID estimates. It is difficult to 
deduce which of these is dominant, but it is likely that at least one of them will 
impact the MCID estimate.  
5.6.4.4 Changing management or estimating base level 
Studies I-V all focus on patient factors not subjected to change as the definition 
of MCID suggests. It is therefore difficult to apply the MCID concept to patient 
factors; they are mostly useful in assessing patients’ base level and their potential 
to achieve MCID with the surgery. They can also help us identify risk groups, 
such as the women in Charnley class C identified in study III.  
In study V we did find a potential factor that could cause a change in 
management. Although our finding needs further investigating, we believe that it 
may be sensible to avoid discontinuation of antidepressant soon before surgery, 
and that the risk is almost negligible unless the patient is experiencing some side 
effects. The risk in considering a change in management is important, as 
suggested by the MCID’s definition: 
      
                     
    
 
If the risk increases, the effect size from the change should also be greater. For 
instance changing a paragraph in pre-operative patient information would require 
an estimated effect equal to the MCID. Conversely, switching surgical technique 
to minimally invasive surgery would require a considerably larger improvement. 
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5.7 BALANCING COMPLEXITY 
One of the main aims with statistics is summarizing and presenting a 
comprehensive outline of the relationships in the data. For large data sets with 
multiple outcomes, a conflict can arise between the overview and the details, 
inhibiting wider understanding of the results [261]. E.g. in study II the main 
emphasis is on the negative impact of age after the late 60s, although the 
supplemental analysis exhibits more patterns available in the data. The simpler 
form of presenting the age relationship was chosen in order to introduce the 
complex idea of non-linear relationships. 
Apart from opting for simpler relations, the studies in this thesis rely heavily on 
graphics. Graphs can present complex relationships and allow comparison 
between multiple values [262, p. 87]. The difficulties in understanding patient-
reported outcomes have been approached by visually contrasting different 
groups. Contrasting them is an alternative approach to the MCID; by using 
references familiar to orthopaedic surgeons it is possible to convey the effect of 
the studied variable even though the outcome measure may be unfamiliar to 
him/her. 
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6 CONCLUSIONS 
6.1 STUDY I 
We failed to validate any of the scores for re-operations after total hip 
arthroplasties, although the Elixhauser score may be useful for estimating the 
comorbidities relevant for the risk of re-operation within 2 years. The 
comorbidities were rare and the associated risk increase was small, thereby it is 
undoubtedly best suited when studying large samples and not individual patients. 
6.2 STUDY II 
There is a non-linear relationship for age and HRQoL in patients receiving THR 
that results in residual confounding if treated as a simple linear term or 
categorically in the regression. The implication of this is important, as age is a 
common confounder for which adjustment is necessary.  The same applies to the 
preoperative EQ-5D index and EQ VAS.  
6.3 STUDY III 
The self-administered Charnley classification is a reliable instrument with 
interesting properties easy to utilize in everyday clinical practice. There is also 
strong evidence that women in Charnley class C fail to improve their mobility as 
much as men. 
6.4 STUDY IV 
There are clear similarities in how basic predictors influence patient-reported 
outcomes in patients with THR in Sweden and Denmark. Apparent cultural, 
social, and other such differences among these countries are not reflected in 
these predictors.  
6.5 STUDY V 
Antidepressants have a negative influence on PROMs 1 year after THR 
independent of the pre-operative EQ-5D anxiety/depression dimension. We also 
found that discontinuation with treatment prior to surgery is associated with 
poorer outcomes in the pain and satisfaction dimensions. 
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7 FUTURE PERSPECTIVES 
The variety of reported results suggests that there is a need for more structured 
reporting and analysis. While many studies have their own unique angle, these 
should most likely be accommodated with standard metrics. It would be 
beneficial if supplements contained basic patient factors such as sex and age 
accompanied by unadjusted estimates, adjusted only according to a standard 
model, and fully adjusted according to the study protocol. This is an important 
piece as comparing effect estimates between populations permits to move the 
debate beyond simple factors such as gender and age. 
In large registry studies the use of categories is a misguided desire for 
simplification. Simplification can be achieved through tables that contrast non-
linear estimates and that can easily substitute the need for categories (see Table 2 
under the results for study II). If cut-off values are of interest, an alternative can 
be piecewise linear regression [263], [264]. With sample sizes well above 
100,000 patients and small effect estimates, the choice of statistical methods is 
increasingly important. 
Understanding complex systems can further be enhanced by interactive graphics. 
Data-Driven Documents (D3) have gained a lot of interest and are currently 
often used by major newspapers such as the New York Times [265], [266]. 
Today, 20 years after the journals started publishing PDFs online, the next step 
of interactive graphics could revolutionize the understanding of research. 
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9 SAMMANFATTNING PÅ SVENSKA 
Bakgrund 
Grundläggande patientfaktorers betydelse för risken för omoperation och 
patientrapporterade utfall efter höftledsplastiker är dåligt kartlagda. 
Syften 
Målen med denna avhandling var att undersöka: 
1. Om samsjuklighetsmått utvecklade för dödlighetsutfall även går att 
applicera på omoperationer. 
2. Hur ålder påverkar hälsorelaterad livskvalitet ( HRQoL ). 
3. Om kön/ålder interagerar med den själv-administrerad Charnley-
klassifikationens inverkan på HRQoL . 
4. Generaliserbarheten mellan länder av HRQoL effekter. 
5. Om antidepressiv användning påverkar patientrapporterade utfall . 
Metoder 
Alla studier baseras på Svenska Höftprotesregistrets (SHAR) databas. För studie 
I har data från SHAR korsmatchats med Patientregistret. Genom matchningen 
kunde 3 olika samsjuklighetsindex beräknas: Charlsons index, Elixhausers index, 
och Royal College of Surgeons (RCS) Charlson index. De tre indexen jämfördes 
sedan med hjälp av överlevnadsanalys avseende omoperationer mellan 0 till 2 år 
och 2 till 12 år. 
I studie II och III användes SHARs databas med patientrapporterade utfall där 
HRQoL mätts med EQ-5D och EQ-VAS. I studie II modelleras ålder med hjälp 
av linjär regression i kombination med splines. I studie III användes linjär 
regression med interaktionsvariabler som utvärderades med hjälp av ANOVA-
tester, undergruppsanalyser och EQ-5D dimensions-specifika analyser. 
I studie IV länkade vi SHARs databas med patientrapporterade utfall till 
Patientregistret för beräkning av Charlsons index. Denna kohort slogs sedan ihop 
med en mindre dansk kohort som också länkats till den danska motsvarigheten 
till Patientregistret för samma beräkning. Därefter undersöktes kön, ålder, 
samsjuklighetseffekt med hjälp av interaktionstermer såsom i studie III. 
I studie V, korsmatchades SHARs databas med patientrapporterade utfall mot 
Läkemedelsregistret. Vi beräknade användningen av antidepressiva läkemedel 
med hjälp av reguljära uttryck (regular expressions). Mått för behandlings-
efterlevnad, förändring i behandling, och indikation hämtades från 
förskrivningstexten. 
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Resultat 
Studie I 
I den tidigt postoperativa perioden, 0-2 år, visade bara Elixhausers index en 
signifikant ökad risk med ökad risk för både 1-2 och ≥ 3 sjukdomstillstånd. Den 
prediktiva C-statistiken under denna period var dock dålig även för Elixhausers 
index, 0,52. Inget av samsjuklighetsmåtten visade sig vara av värde mellan 2-12 
år. 
Studie II 
Ålder uppvisade ett icke-linjärt samband med HRQoL. Åldern hade knappt 
mätbar inverkan på värdena fram till 60-70 års ålder, varefter den hade en 
negativ inverkan på både EQ-5D index och EQ-VAS. 
Studie III 
Vi fann att kvinnor i Charnley klass C hade ett sämre EQ-5D utfall jämfört med 
män. Denna effekt berodde främst på det faktum att kvinnor inte förbättrades i 
rörlighetsdimensionen, endast 40 % av kvinnorna blev bättre medan 50 % av 
männen förbättrades. Ålder interagerade däremot inte med Charnley klass. Vi 
fann också att klassificeringen utförs bäst utan delning av B-klassen eller 
aggregerandet av klasser. 
Studie IV 
Danska patienter hade övergripande högre HRQoL jämfört med svenska 
patienter (p-värde < 0,001). En regressionsanalys kunde dock inte påvisa att 
koefficienterna för kön, ålder eller Charlsons index skiljer sig åt mellan länderna 
(EQ - 5D-index p-värde = 0,83 och EQ VAS p-värde = 0,41) 1 år efter THR. 
Studie V 
Antidepressiva läkemedel användes av 9 % av patienterna (n = 954). Patienter 
som använder antidepressiva medel rapporterade även sämre HRQoL, mer 
smärta, och upplevde mindre tillfredsställelse 1 år efter operation. Den negativa 
effekten av preoperativ antidepressiv användning var oberoende av patient-
rapporterade ångest eller depression (mätt enligt EQ-5D) 1 år efter THR. 
Utsättning av behandlingen var också negativt associerat med smärta och 
tillfredsställelse efter 1 år. 
Slutsatser 
Studie I 
Vi misslyckades med att validera något av samsjuklighetsmåtten för 
omoperationer efter höftledsproteser, även om Elixhausers index kan vara 
användbart för att uppskatta samsjuklighet relevant för reoperationsrisken inom 
2 år. Riskökningen associerade samsjuklighet var liten och är utan tvekan bäst 
lämpad för studier av stora populationer och inte enskilda patienter. 
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Studie II 
Det finns ett icke-linjärt förhållande mellan ålder och hälsorelaterad livskvalitet 
ett år efter en höftledsplastik; detta innebär att man inte kommer att justera bort 
all den effekt som en patients ålder medför om den behandlas som en enkel linjär 
variabel eller delas upp i kategorier. Innebörden av detta är viktig eftersom ålder 
är en vanlig confounder. Detsamma gäller för de preoperativa HRQoL värdena. 
Studie III 
Den självadministrerade Charnleyklassifikationen är ett tillförlitligt instrument 
med intressanta egenskaper som är lätt att använda i den kliniska vardagen. Det 
finns dessutom mycket som talar för att kvinnor i Charnley klass C misslyckas 
med att förbättra sin rörlighet lika mycket som män. 
Studie IV 
Det finns klara likheter i hur grundläggande prediktorer påverkar 
patientrapporterade utfall efter höftledsplastiker mellan svenska och danska 
patienter. Skenbara kulturella, sociala och andra sådana skillnader mellan dessa 
länder tycks inte återspeglas i dessa prediktorer. 
Studie V 
Antidepressiva medel har en negativ inverkan på patientrapporterade utfall 1 år 
efter en höftledsplastik, oberoende av den preoperativa ångest eller depression 
mätt enligt EQ-5D:s femte dimension. Vi fann också att om behandlingen 
avbröts före kirurgi var detta förknippat med sämre resultat gällande 
smärtlindring och tillfredsställelse. 
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